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Résumé 
 
Le neuroblastome (NB) est un néoplasme dévastateur de la petite enfance, pour 
lequel il n’existe pas encore de traitement efficace. Les chimiokines et leurs 
récepteurs ont été impliqués dans la croissance des tumeurs et la formation de 
métastases, et en particulier, il a été rapporté que l’axe CXCR4/CXCL12 dirigeait le 
guidage, ainsi que l’invasion des cellules cancéreuses vers des organes spécifiques. 
Notre étude avait pour objectif d’analyser le rôle de CxCR4 exogène dans le 
comportement malin du NB, en étudiant la croissance des cellules tumorales, leur 
capacité de survie, de migration et d’invasion in vitro et en validant ces résultats 
grâce à un modèle orthotopique murin de la progression tumorale du NB in vivo. 
La surexpression de CXCR4 dans les cellules faiblement métastatiques IGR-NB8 
n’exprimant pas CXCR4, a augmenté la mobilité des cellules vers CXCL12 in vitro. 
 
De plus, les cellules surexprimant CXCR4 ont été moins affectées par la  privation de 
sérum que les cellules contrôles. Le volume des tumeurs chez les animaux greffés 
de manière orthotopique avec les cellules NB8-CXCR4-C3 était significativement 
plus élevé que celui des tumeurs issues des cellules contrôles NB8-E6 au moment 
du sacrifice des animaux. Cependant, aucune induction des métastases n’a été 
observée. 
La lignée cellulaire IGR-N91, aux propriétés invasives et métastatiques in vivo, 
exprime constitutivement des quantités modérées de CXCR4. La surexpression du 
récepteur dans cette lignée a accéléré la croissance tumorale in vivo, mais n’a pas 
augmenté pas l’occurrence des métastases. Les cellules IGR-N91, dans lesquelles 
l’expression de CXCR4 a été éteinte, suite à l’introduction de shRNA stable contre 
CXCR4, a présenté une croissance cellulaire plus lente, in vitro et in vivo. 
Afin d’identifier les gènes et les voies de signalisation impliqués dans les effets 
dépendants de CXCR4-CXCL12 dans le NB, des analyses du profil d’expression des 
gènes ont été effectuées sur les lignées cellulaires transfectées ou non (contrôle). 
Trois clones contrôles ont été comparés à 3 clones surexprimant CXCR4 pour 
chacune des lignées (IGR-NB8 et IGR-N91). Les analyses biostatiques ont identifié 
10 gènes induits, dont CXCR4, et 31 gènes réprimés, communs entre tous les clones 
surexprimant CXCR4. 
Ces observations démontrent que la surexpression de CXCR4 dans le NB stimule la 
croissance, la survie et la migration chémotactique des cellules tumorales, mais est 
insuffisante pour induire ou augmenter leurs capacités invasives et métastatiques.  
Les voies de signalisation activées suite à la surexpression de CXCR4 et identifiées 
à travers le profil global de l’expression des gènes pourraient être des cibles 
intéressantes pour le développement de drogues capables d’inhiber la croissance 
tumorale. 
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Summary 
 
Neuroblastoma (NB) is a devastating childhood neoplasm for which there is not yet 
an efficient treatment. Chemokines and their receptors have been involved in tumour 
growth and metastasis, and in particular the CXCR4/CXCL12 axis has been reported 
to mediate organ-specific cancer cells homing and invasion. The purpose of the 
study was to investigate the role of ectopic CXCR4 in the malignant behaviour of NB 
by studying tumour cell growth, survival, migration, and invasion in vitro and by 
validating these results using a murine orthotopic model of NB tumour progression in 
vivo.  
CXCR4 overexpression in the low metastatic, CXCR4-negative IGR-NB8 cells 
resulted in CXCL12-mediated chemotaxis in vitro. Furthermore, CXCR4 
overexpressing cells were less affected by serum deprivation than mock-transduced 
cells. In vivo studies revealed that, at sacrifice, volumes of tumours developing in 
mice with orthotopically implanted NB8-CXCR4-C3 cells, were significantly increased 
compared to NB8-E6 control tumours. However, no induction of metastases was 
observed.  
The in vivo invasive and metastatic cell line IGR-N91 cell line constitutively 
expresses moderate levels of CXCR4. Overexpression of CXCR4 enhanced in vivo 
tumour growth but did not increase the occurrence of metastases.  
IGR-N91 cells where CXCR4 has been knocked-down by stable shRNA grew slower 
in vitro and in vivo.  
To identify genes and pathways involved in the CXCR4/CXCL12-mediated effects in 
NB expression, profiles analyses (Affymetrix) were performed on transduced and 
control cell lines. Three mock-transduced clones were compared to three CXCR4 
overexpressing clones of either cell line IGR-NB8 and IGR-N91. Biostatistical 
analysis identified 10 commonly upregulated genes (including CXCR4) and 31 
downregulated genes common to all CXCR4 overexpressing clones.  
These observations demonstrate that overexpression of CXCR4 in NB stimulates 
tumour cell growth, survival, and chemotactic migration but is not sufficient to induce 
or enhance invasive and metastatic capacities.  
Activated pathways upon CXCR4 overexpression, identified through global gene 
expression profiling may be interesting targets for drugs inhibiting tumour growth. 
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Abbreviations 
 
ALK:  anaplastic lymphoma kinase  
BDNF:  brain-derived neurotrophic factor 
bFGF:  basic fibroblast growth factor 
BSA:  bovine serum albumine 
Ca2+:  calcium-cation 
CAF:  cancer associated fibroblasts 
CDC42: cell division cycle 42 (GTP binding protein, 25kDa) 
CHD5:  chromodomain helicase DNA binding domain 5 
DAFL: DNA array facility Lausanne 
DCC:  deleted in colorectal cancer 
DMEM:  Dulbecco's Modified Eagle Medium   
dNTP: deoxynucleotide triphosphate 
DNA:  deoxyribonucleic acid 
DTT: dithiothreitol 
ECM:  extracellular matrix 
ECL:  enhanced chemiluminescence 
EDTA:  ethylenediaminetetraacetic acid 
EGFR:  epidermal growth factor receptor 
EGTA:  ethylene glycol - bis(beta - aminoethyl ether) - N,N,N',N' tetra-
 acetic acid 
ELISA:  Enzyme Linked ImmunoSorbent Assay 
ERK 1/2:  extracellular signal-regulated kinase 1 and 2 
FACS:  fluorescence activated cell sorting 
FCS:  foetal calf serum 
FDR: false detection rate 
GAPDH: glyceraldehyde 3-phosphate dehydrogenase 
GP:  glycoprotein 
GTPase: guanosyl triphosphatase 
GFP:  green fluorescent protein 
GFP-IHC: GFP-Immunohistochemistry  
GPCR:  G-protein coupled receptor 
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H/E:  haematoxylin / eosin 
HRP: Horse radish peroxydase 
HVA: homovanillic acid 
IGR: Institut Gustave Roussy 
IL-8:  interleukin 8 
i.p.: intraperitoneal 
LDH:  lactate dehydrogenas 
LOH: loss of heterozygosity 
MAPK:  mitogen-activated protein kinases 
mdr-1:  multidrug resistance gene 1  
MDR:  multidrug resistance  
MMP:  matrix metalloproteinase 
MLCK myosin light chain kinase 
MRP:  multidrug resistance protein 
MTS/PMS: (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
 (4-sulfophenyl)-2H-tetrazolium)/phenazine methosulfate 
NB:  neuroblastoma 
NGF:  nerve growth factor 
NSE:  neuron specific enolase 
NTR: neurotrophin receptor 
OD:  optical density  
p75NTR:  p75 neurotrophin receptor 
PBS: phosphate buffer solution 
PE:  phycoerythrin 
p-ERK 1/2: phosphorylated ERK 1 and 2 
p-gp:  p-glycoprotein 
RANTES:  Regulated on Activation, Normal T Expressed and Secreted 
RET:  rearranged during transfection 
RNA:  ribonucleic acid 
ROCK: rho-kinase 
RT:  room temperature 
RT-PCR: real-time PCR 
S.D.:  standard deviation 
SDS-PAGE:  Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
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SFM:  serum free medium  
TBS: tris buffer solution 
t-ERK 1/2: total ERK 1 and 2 
TGF-α: transforming growth-factor α 
TGF-β:  transforming growth-factor β 
Trk:  tyrosine kinase 
VEGF:  vascular endothelial growth factor 
VMA: vanillyl mandelic acid 
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Introduction 
 
Carcinogenesis 
 
Over the past decades cancer research has generated a rich and complex body of 
knowledge, revealing cancer to be a disease involving dynamic changes in the 
genome. These modifications involve both, the activation of oncogenes and the 
inactivation of tumour suppressor genes. They may occur as the direct result of the 
actions of exogenous mutagens, such as chemicals, radiation or viruses. The genetic 
alterations may also be of endogenous origin, resulting from the mutagenic action of 
chemical products generated during physiological processes such as senescence. 
Finally, some of these mutations may be inherited in the germ line and are 
responsible for rare familial cancer syndromes. Independently of the underlying 
genetic alteration, cancer cells acquire new capacities, called „hallmarks of cancers“. 
These hallmarks represent common changes of six alterations in cell physiology that 
collectively dictate malignant growth (1): 
 
• self sufficiency in growth signals 
• insensitivity to antigrowth signals 
• evading apoptosis 
• limitless replicative potential  
• sustained angiogenesis 
• tissue invasion and metastasis 
 
 
Cancer environment 
 
Cancer is not an autonomous process intrinsic to the cancer cells. This view would 
omit a central biological reality of tumour formation in vivo: cancer development also 
depends on changes in its environment. Hence, the microenvironment of a cancer 
must be taken into consideration when investigating cancer behaviour. The 
significant contribution of stroma to tumour development and to the active support of 
tumour growth has been supported by extensive clinical and mouse model evidence 
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(2-5). As an example, Orimo et al. found that fibroblasts present in the invasive 
human mammary carcinoma mass are biologically very different from their 
counterparts outside of the tumour mass and from normal mammary stromal 
fibroblast (6). When co-injected with cancer cells CAF gave rise to highly 
vascularized tumours, whereas the normal fibroblasts did not increase tumour 
vascularization.  
 
 
Metastasis  
 
The process of cancer metastasis consists of a long series of sequential, interrelated 
selective steps that only few cells are able to complete. Each of these steps can be 
rate limiting (7). The outcome of the process is dependent on both the intrinsic 
properties of the tumour cells and the responses of the host (8). During tumour 
progression, cancer cells acquire multiple further alterations that render them 
increasingly competent to metastasise to specific organs. Multiple genes have been 
described to play a key role in the establishment of metastases, but how they 
cooperate to fulfil various requirements for the establishment of tissue-specific 
metastases is not fully determined (8, 9). In addition, the development of metastases 
does not represent the random survival and growth of few cancerous cells, but the 
selective growth of unique subpopulations of malignant cells endowed with special 
properties, and predilection for specific organs, which involve both the tumour cells 
and the target tissue (1, 10).  
 
 
Metastasis and microenvironment 
 
The sites of metastasis are determined by the characteristics of the neoplastic cells 
and by the microenvironment of the host tissue (7-9). Microenvironment of different 
organs is biologically unique and its cross talk with the invasive cells will determine 
the extent of cancer cell proliferation, survival, and neoangiogenesis. Evidence 
indicates that molecular factors present in the microenvironment of specific organs 
can influence the implantation and growth of various types of cancer cells (8, 11). 
Tumour cells will respond differently, in terms of gene expression and growth rate, 
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depending on the environment characteristics of every organ. The complex 
mechanisms determining the directional migration and invasion of tumour cells into 
specific organs still remain poorly understood (12, 13). Cancer cells do not form 
metastases at random sites but each tumour has a distinct pattern of metastases. 
Clinical observations of cancer patients and studies in rodent models of cancer have 
revealed that certain tumour types tend to metastasize to specific organs, 
independently of vascular anatomy, rate of blood flow, and the number of tumour 
cells delivered to each organ (7, 14). 
Some of the essential molecular factors that influence the ability of cancer cells to 
grow in specific organs have been identified. They include the expression of specific 
growth-factor receptors on the cancer cells such as the epidermal growth factor 
receptor (EGFR), coupled with expression of growth factors in the tissue, like 
transforming growth factor-α (11). Endothelial cells in the vasculature of different 
organs express different cell-surface receptors (15, 16) and growth factors that 
influence the phenotype of metastases develop (16). The organ microenvironment 
also influences the pattern of gene-expression of cancer cells (6). The expression 
level of various proteolytic enzymes of tumour cells is dependent on the secondary 
organ environment (17, 18). Studies testing orthotopic, versus ectopic implantation of 
tumour cells in vivo, have revealed that expression of invasion-related genes 
encoding for collagenase, or angiogenesis-related genes encoding for bFGF, IL-8, or 
mdr-1, was increased in cells with high metastatic potential (9).  
 
 
Tumour cell migration and invasion  
 
The complex multistep process of metastasis starts with cancer cell detachment from 
the primary tumour, and invasion to the extracellular matrix. The tumour cells 
equipped with the proper machinery will further invade vessels (intravasation) and 
migrate into the surrounding tissue (extravasation). Cells that survive a considerable 
death pressure during these stages have the potential to form metastases at distant 
sites (19). 
The acquisition of motility and invasive properties enabling tumour cells to migrate 
into adjacent tissues or to transmigrate limiting basement membranes and 
extracellular matrices are key events in the oncogenic progression of cells. Invasive 
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tumour cells have been demonstrated to present deregulated cell motility in response 
to extracellular signals from growth factors and cytokines (20). Oncogenic 
deregulation can induce a switch from a stable adherent phenotype to a motile and 
invasive one. The transition from a normal to an invasive phenotype requires drastic 
reprogramming on a genetic and physiological level, which results in a number of 
crucial changes.  
Adhesive capacities of the cancer cells are being abolished and transitorily activated. 
The actin cytoskeleton is remodelled and chemotactic and haptotactic cues are 
recognized. Subsequently ECM proteins are processed and secreted along the 
trajectory. 
In order to perform these changes, cells need to modulate a variety of signalling 
pathways and to change their transcriptional profiles (21). The multiple molecules 
and pathways involved in such processes have only been partially identified. 
Although, tumour metastatic dissemination may follow the pathway of leukocytes 
extravasation and involve a cascade of steps mediated by integrins, chemokines,  
cytokines, selectins, and their ligands (22, 23). 
Cell locomotion depends on a highly orchestrated set of events involving the 
polymerization and de-polymerization of actin filaments and the exertion of force 
through actinomyosin-mediated contraction. There is evidence that directly links 
elevated expression of Rho to the acquisition of migratory, invasive, and metastatic 
phenotypes (24, 25). Members of the Rho family of GTPases play a central role in 
the regulation of the actin cytoskeleton, with RhoA, Rac and CDC42 influencing 
stress fibres, lamellipodia, and filopodia respectively (26). The overexpression or 
activation of the Rac, Rho, Rock or MLCK signalling pathways have been correlated 
with in vitro tumour-cell migration, as well as in vivo invasion and progression (25, 
27-29). Rho GTPases are activated by different classes of transmembrane receptors 
and transmit these signals to their effector proteins. These downstream targets 
include not only adaptor proteins and kinases which affect the actin cytoskeleton, but 
also transcription factors leading to an altered expression of genes necessary for the 
drastic morphological changes which accompany motility and invasion processes 
(25). 
In addition ECM-degrading enzymes, such as MMPs and cathepsins, have been 
reported to be frequently up regulated in tumour cells (29, 30), and to facilitate 
migration in vitro (31), as well as dissemination and metastasis in vivo (28-30).  
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Chemokines and their specific receptors 
 
Chemokines are a super family of small, cytokine-like proteins. Based on the 
positions of 2 conserved cysteine residues in their N- termini, chemokines are divided 
into four families: CC, CXC, CX3C, and C (32, 33). The two major families are the 
CXC and CC chemokines, which interact with transmembrane G-protein-linked CXC 
and CC receptors respectively. Binding of chemokines to their cognate receptors 
induces G-protein-mediated responses such as cytoskeletal rearrangement, firm 
adhesion to endothelial cells, and directional migration (34, 35). 
 
 
Figure 1: Activation of chemokine signalling can result in several changes in cells, including 
activation of RAS/MAPK signalling pathways, polymerization of intracellular actin and cytoskeletal 
changes, formation of pseudopodia, and increased cell motility, migration and tissue invasion (8). 
 
 
Recent studies have shown that some tumour cells express patterns of chemokine 
receptors that 'match' chemokines which are specifically expressed in organs to 
which these cancers commonly metastasize, suggesting that chemokines and their 
receptors may have a critical role in determining the metastatic destination of tumour 
cells (36-38). Moreover, because chemokines are involved in the 'homing' of 
lymphocytes, it is tempting to postulate that they also cause cancer cells to 'home' to 
specific secondary sites, thereby promoting organ-specific metastasis (10, 39). Such 
hypothesis is further supported by the finding that chemokine/receptor interactions 
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can trigger signalling pathways that lead to various cellular functions such as actin 
polymerisation, invasion, formation of pseudopodial projections, and activation of the 
RAS/MAPK pathways (34, 35, 40). 
Human breast cancer cell lines and human primary breast tumours were found to 
express the chemokine receptors CXCR4 and CCR7 at high levels. Their specific 
ligands, CXCL12 and CCL21 were also found at high levels in lymph nodes, lung, 
liver and bone marrow, the first destinations of several metastatic cancer cells 
including breast cancer and neuroblastoma (34, 41-44). The chemokines 
CXCL9/Mig, CXCL10/IP-10, and CXCL11/I-TAC are known to regulate lymphocyte 
chemotaxis, to mediate vascular pericyte proliferation, and to act as angiostatic 
agents, thus inhibiting tumour growth (45). These chemokines present in the 
microenvironment of neural crest-derived tumours, potentially bind to their tumour-
bearing receptors (46). Taken together, these observations strongly suggest that 
chemokines and their receptors play a key role in determining the metastatic 
destination of tumour cells. 
 
 
CXCR4/CXCL12 axis in tumour growth and metastasis 
 
The G protein-coupled 7-transmembrane chemokine receptor CXCR4 was originally 
described as a lymphocyte homing factor and as a major cofactor for the fusion and 
entry of HIV (47). It binds to the unique ligand, CXCL12, also known as stromal cell-
derived factor-1. CXCR4 knock out mice show impaired haematopoiesis, heart 
defects, altered cerebellar development and die in utero from such severe defects in 
organogenesis. Interestingly, identical defects are observed in mice lacking the 
CXCL12 ligand, suggesting an unusual monogamous relationship between CXCR4 
and CXCL12. These observations also support CXCR4/CXCL12 as a major 
signalling axis involved in development (48, 49). However, recently two groups 
independently described CXCR7 as a new receptor for CXCL12. The function and 
role of CXCR7 is not fully elucidated yet and the two reports on CXCR7 were not 
entirely concordant (50, 51). 
Malignant cells from at least 23 different types of cancer, including NB, express the 
chemokine receptor CXCR4 and respond to its ligand CXCL12. This receptor ligand 
complex appears to be involved in directed migration of cancer cells to sites of 
 Introduction 
- 23 - 
metastasis, increased survival of cancer cells in sub optimal conditions and 
establishment of a tumour promoting cytokine/chemokine network (12, 38, 44, 52, 
53). Neutralising the interactions of CXCR4/CXCL12 in vivo, significantly impaired 
metastasis of breast cancer cells to regional lymph nodes and lung (36, 44, 53, 54). 
 
 
Neuroblastoma 
 
Neuroblastoma (NB), the most common and deadly solid tumour in childhood, 
originates from primitive cells of the sympathetic nervous system (55). This neoplasm 
displays an extremely heterogeneous behaviour at clinical, biological, and genetic 
levels. Its incidence is about 1 of 100 000 live birth and it accounts for 7 % - 10 % of 
all cancer related deaths in childhood (56). 
The origin and migration pattern of neuroblasts during foetal development explains 
the multiple anatomic sites where these tumours occur; location of tumours appears 
to vary with age. Tumours can occur in the abdominal cavity (40% adrenal, 25% 
paraspinal ganglia) or involve other sites (15% thoracic, 5% pelvic, 3% cervical 
tumours, 12% miscellaneous). Infants more frequently present with thoracic and 
cervical tumours, whereas older children more frequently have abdominal tumours. 
(55). 
 
According to the International Neuroblastoma Staging System the tumours are 
divided into 4 different stages (Figure 2) (57). 
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Figure 2: International neuroblastoma staging system (INSS) 
Stage 1  
• Localized tumour with complete gross excision and/or microscopic residual disease  
• Ipsilateral lymph nodes negative for tumour (nodes attached to the primary tumour may be 
positive for tumour.) 
Stage 2A  
• Localized tumour with incomplete gross resection  
• Representative ipsilateral nonadherent lymph nodes negative for tumour microscopically 
Stage 2B  
• Localized tumour and/or complete gross excision, with ipsilateral nonadherent lymph nodes 
positive for tumour  
• Enlarged contralateral lymph nodes, which are negative for tumour microscopically 
Stage 3  
• Unresectable unilateral tumour infiltrating across the midline and/or regional lymph node 
involvement  
• Alternately, localized unilateral tumour with contralateral regional lymph node involvement 
Stage 4  
• Any primary tumour with dissemination to distant lymph nodes, bone, bone marrow, liver, skin, 
and/or other organs (except as defined for stage 4S) 
Stage 4S  
• Localized primary tumour (as defined for stages 1, 2A, or 2B) with dissemination limited to 
skin, liver, and/or bone marrow (<10% involvement)  
• Limited to infants  
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While most infants experience complete regression of their disease with minimal 
therapy, the majority of older patients presents with a high stage and disseminated 
disease that will progress despite intensive multi-modality treatments. Metastatic 
dissemination of advanced stage tumours mainly occurs in the bone marrow, bone, 
liver and skin. Bone marrow involvement and clearing are key prognostic factors for 
NB (58). Interestingly, the particular and more benign NB stage IVs, associated with 
a good prognosis, presents a unique and unexplained pattern of metastatic spread 
limited to bone marrow, liver, and skin. As for many cancers, metastases are the 
most fearsome aspect of NB and despite significant improvements in diagnosis, and 
local and systemic adjuvant therapies, most deaths from NB are related to treatment-
resistant metastatic disease. Therefore, understanding the pathogenesis of 
metastatic spread on the systemic, cellular and molecular levels is an essential 
challenge of cancer research. Targeting the different steps of the metastatic process 
could allow the development of efficient adjuvant therapies for NB and other 
aggressive neural crest-derived tumours.  
Most patients present with signs and symptoms related to tumour growth, although 
small tumours are detected in infants on prenatal ultrasound. Large abdominal 
tumours often result in increased abdominal girth and other local symptoms (i.e., 
pain). Paraspinal tumours can extend into the spinal canal, impinge on the spinal 
cord, and cause neurological dysfunction.  
Stage of the tumour at the time of diagnosis and age of the patient are the most 
important clinical prognostic factors. Although patients with localized tumours 
(regardless of age) have an excellent outcome (80-90% 3-year event-free survival 
(EFS) rate), patients older than 1 year with metastatic disease fare poorly. Generally, 
more than 50% of patients present with metastatic disease at the time of diagnosis, 
20-25% have localized disease, 15% regional extension, and approximately 7% 
present during infancy with disseminated disease limited to the skin, liver, and bone 
marrow (stage 4S) (59). 
Fewer than half of these patients are cured, even with the use of high-dose therapy 
followed by autologous bone marrow or stem cell rescue (60, 61). 
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Biochemical markers for NB and mass screening 
 
More than 90% of patients have elevated homovanillic acid (HVA) and/or 
vanillylmandelic acid (VMA) detectable in urine. Mass screening studies were using 
urinary catecholamines in neonates and infants in Japan, Quebec, and Europe (62-
65). These large screening studies were eventually abandoned because incidence of 
poor prognostic disease was not decreased. However, most of the tumours identified 
using this method revealed to be tumours with a favourable prognosis. No data exist 
to suggest that mass screening has decreased deaths from high-risk neuroblastoma. 
Markers associated with a poor prognosis are elevated ferritin (66), serum LDH (67), 
and serum NSE (68).  
 
 
Histology of NB tumours  
 
Pluripotent sympathetic stem cells migrate and differentiate to form the different 
organs of the sympathetic nervous system during development. The normal adrenal 
gland consists of chromaffin cells, which produce and secrete catecholamines and 
neuropeptides. Other cells are similar to Schwann cells, and scattered ganglion cells. 
Histologically, neural crest tumours can be classified as neuroblastoma, 
ganglioneuroblastoma, and ganglioneuroma, depending on the degree of 
maturation/differentiation of the tumour (69). 
Undifferentiated neuroblastomas histologically present as small, round, blue cell 
tumours with dense nests of cells in a fibrovascular matrix and Homer-Wright 
pseudorosettes. These pseudorosettes, which are observed in 15-50% of tumour 
samples, can be described as neuroblasts surrounding eosinophilic neuritic 
processes. The typical tumour shows small uniform cells with scant cytoplasm and 
hyperchromatic nuclei. A neuritic process, also called neuropil, is a pathognomonic 
feature of neuroblastoma cells. NSE, chromogranin, synaptophysin, and S-100 
immunohistochemical stains usually are positive. Electron microscopy can be useful 
because ultrastructural features (e.g., neurofilaments, neurotubules, synaptic 
vessels, dense core granules) are diagnostic for neuroblastoma. 
In contrast, the completely benign ganglioneuroma typically is composed of mature 
ganglion cells, Schwann cells, and neuritic processes, whereas 
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ganglioneuroblastomas include the whole spectrum of differentiation between pure 
ganglioneuromas and neuroblastomas. Because of the presence of different 
histologic components, the pathologist must evaluate the tumour thoroughly; the 
regions with different gross appearance may demonstrate a different histology. 
Neuroblastic nodules are present in the human foetal adrenal gland and peak at 17 - 
18 weeks' gestation. Most of these nodules regress spontaneously and likely 
represent remnants of foetal development. It is believed that some of these may 
persist and lead to the development of neuroblastoma (70). 
 
 
Chromosomal and molecular markers  
 
During the last 2 decades, many chromosomal and molecular abnormalities have 
been identified in neuroblastoma (59, 71). These biologic markers have been 
evaluated to determine their value in assigning prognosis, and some of these have 
been incorporated into the strategies used for risk-assignment.  
The most important and first identified of these biologic markers is MYCN (72). 
MYCN is an overexpressed oncogene in neuroblastoma with the amplification of the 
distal arm of chromosome 2. This gene is amplified in approximately 25% of de novo 
cases and is more common in patients with advanced-stage disease. Patients whose 
tumours have MYCN amplification tend to have rapid tumour progression and a poor 
prognosis. In contrast to MYCN, expression of the H-ras oncogene correlates with 
lower stages of the disease (73). Cytogenetically, the presence of double minute 
chromatin bodies and homogeneously staining regions correlates with MYCN gene 
amplification.  
Deletion of the short arm of chromosome 1 is the most common chromosomal 
abnormality present in neuroblastomas, and is associated with a high risk of relapse 
and poor prognosis. The 1p chromosome region likely harbours tumour suppressor 
genes or genes that control neuroblast differentiation. Deletion of 1p is more common 
in near-diploid tumours and is associated with a more advanced stage of the disease. 
Most of the deletions of 1p are located in the 1p36 area of the chromosome (74, 75). 
A relationship between 1p loss of heterozygosity (LOH) and MYCN amplification has 
been described (76). CHD5, a tumour suppressor gene was recently found in that 
region which could also be implicated in NB development (77). 
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Other allelic changes such as loss of 1p, 3p, 4p, 10q, and 11q, gain of 2p and 17q 
have been reported. The expression profiles of regions where genetic alterations 
occur suggest some candidate genes involved in NB progression (78-80). The DNA 
index is another useful test that correlates with response to therapy in infants. Look 
et al. demonstrated that infants whose neuroblastomas have hyperdiploidy (DNA 
index >1) have a good therapeutic response to cyclophosphamide and doxorubicin. 
In contrast, infants whose tumours have a DNA index of 1 are less responsive to the 
latter combination and require more aggressive therapy (81). DNA index does not 
have any prognostic significance in older children. In fact, hyperdiploidy in children 
more frequently occurs in the context of other chromosomal and molecular 
abnormalities that confer a poor prognosis (82). 
Three neurotrophin receptor gene products, TrkA, TrkB, and TrkC, are tyrosine 
kinases that code for a receptor of members of the nerve growth factor (NGF) family. 
Their ligands include p75 neurotrophin receptor (p75NTR) NGF, and BDNF's. 
Interestingly, TrkA expression is correlated inversely with the amplification of the 
MYCN gene, and the expression of the TrkC gene is correlated with TrkA expression. 
In most patients younger than 1 year, a high expression of TrkA correlates with a 
good prognosis, especially in patients with stages 1, 2, and 4S. In contrast, TrkB is 
more commonly expressed in tumours with MYCN amplification. This association 
may represent an autocrine survival pathway (83-87).  
Other biologic markers associated with poor prognosis include increased levels of 
telomerase RNA and lack of expression of glycoprotein CD44 on the tumour cell 
surface (88-91).  
P-gp and MRP are 2 proteins expressed in neuroblastoma. These proteins confer an 
MDR phenotype in some cancers. Their role in neuroblastoma is controversial. MDR 
is one target for novel drug development (92). 
 
 
Neuroblastoma and chemokines 
 
There is accumulating evidence that chemokines are implicated in NB progression. 
The expression of several chemokine receptors on neuroblastoma cells and tumours 
has been linked to their aggressive phenotype. Expression of CXCR4 on NB cell 
lines was proposed to be related to the development of bone marrow metastases in a 
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CXCL12-dependent manner (93). Although CXCR3 has not yet been detected on 
clinical tumour samples, CXCR3 is expressed by several NB cell lines, and its ligand 
CXCL10 was reported to inhibit NB tumour growth and to induce cell death (94-96). 
The MIP1-a, MIP1-b, and RANTES CCR5 ligands, induce cell death in CCR5 
positive NB cells as recently reported (97, 98). The chemokine receptor CCR2 is 
expressed on invariant natural killer cells. Neuroblastoma cell lines and tumours 
produce its only known ligand CCL2. The migration of invariant natural killer cells 
towards NB tumours expressing high levels of CCL2 is increased and correlates with 
more favourable prognosis (99).  
 
 
The CXCR4/CXCL12 axis in neuroblastoma 
 
CXCR4 was found by immunohistochemistry on NB patient samples and its 
expression was associated with advanced stage disease (100). Interestingly, strong 
CXCR4 expression was not only found on metastatic stage 4 tumours but also on 
non-metastatic stage 3 tumours. Furthermore, high levels of functional CXCR4 were 
found on aggressive NB cell lines in vitro and thus it was suggested that CXCR4 
expression may be involved in the development of NB metastases in the bone 
marrow (93). In fact, CXCR4 is frequently found on human NB bone marrow 
metastases samples. However, its role remains controversially discussed (101, 102). 
Airoldi et al. reported that CXCR4 expressed on human NB cells from bone marrow 
samples could not confer migratory capacities to the cancer cells and concluded that 
CXCR4 on NB cells may not be functional. Recently it was suggested that 
overexpression of CXCR4 on NB cells could lead to site specific homing of NB when 
tumour cells are injected intravenously (101). Thus, CXCR4 may be involved in site-
specific homing of NB cells when NB cells are disseminated. However, it remains 
unclear whether CXCR4 can induce or increase metastases when tumour cells grow 
in their natural environment. Furthermore, the CXCR4/CXCL12 axis may play a 
complex role in NB tumour progression since non metastatic stage 3 tumours also 
express CXCR4 (100). Altogether, the role of CXCR4 on NB tumour progression has 
been controversially discussed and still remains elusive. Especially the role of 
CXCR4 on NB cells and their in vivo behaviour, using an orthotopic mouse model, 
has not been addressed yet. 
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The CXCR4/CXCL12 axis and angiogenesis in NB 
 
The CXCR4/CXCL12 axis is also involved in the regulation of angiogenesis. Vascular 
endothelial growth factor (VEGF) is one of the best characterized angiogenic factor 
and its angiogenic action is widely recognized (103). VEGF directly up-regulates 
CXCL12 and CXCR4, and thus increases invasive capacities of glioma cells (104). 
Moreover, VEGF and CXCL12 synergistically induce neo-angiogenesis in ovarian 
cancers (105). Blockade of the CXCR4/CXCL12 axis in colon cancer attenuates in 
vivo tumour growth by inhibiting angiogenesis in a VEGF-independent manner (106). 
Nevo et al. reported an increased VEGF release by NB cells with high CXCR4 
expression as compared to cells with low CXCR4 expression (107). 
 
 
In vivo models to study the development of metastases 
 
As described above, interactions between tumour cells and the metastatic 
microenvironment are extremely complex and selective. Therefore the choice of in 
vivo models is critical for obtaining relevant data on the development of metastasis, 
and subsequently on their control. Killion et al. (108) have shown that faithful 
reproduction of the tumour microenvironment, as in orthotopic models, allows the 
emergence of subpopulation of tumour cells with the biological and metastatic 
properties observed in clinical cancers. These models are of particular interest when 
studying interactions of the tumour and its environment or the vascular system. The 
vast majority of NB xenograft models described consist of primary tumours or cell 
lines implanted to heterotopic (subcutaneous) sites that are not clinically relevant. In 
contrast orthotopic mouse models of NB have the advantage of a more physiologic 
tumour biology environment, an important aspect for the analysis of metastasis-
related mechanisms and genes (109-111). 
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Purpose and aims of the project 
 
Accumulating evidence suggests that the CXCR4/CXCL12 axis is a key player in 
conferring aggressive behaviour to many different types of cancer (38, 38). The 
chemokine receptor CXCR4 has also been found on NB tumour samples in its higher 
stages (100). Furthermore there are reports indicating that this axis may play an 
important role in the development of site specific metastasis in NB progression (93). 
However the role of the CXCR4/CXCL12 axis in NB is controversially discussed 
(102).  
The aim of this project was to elucidate the role of the CXCR4/CXCL12 axis in the 
malignant phenotype of NB in vitro and in vivo. A deeper insight into the properties of 
NB cells conferred by the CXCR4/CXCL12 axis may reveal new therapeutic targets 
for advanced stage disease. 
By CXCR4 gain of function and CXCR4 loss of function experiments in NB cell lines 
we investigated which properties of malignant cells could be induced or increased by 
CXCR4.  
We focused our study on migration, invasion, and cell growth in vitro and on 
metastasis and tumour growth in vivo using an orthotopic mouse model. Biochemical 
analyses were further used to investigate the role of specific proteins and global 
molecular expression profiling to identify genes implicated in the CXCR4/CXCL12 
axis.  
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Materials and methods 
 
Histopathological and immunohistochemistry analyses 
 
For tissue morphology evaluation, standard H/E staining procedures were performed 
on paraffin-embedded human or mouse tissues.  
Immunostaining of CXCR4 of human tumours was performed on paraffin sections of 
NB clinical samples. In accordance with ethical regulations, tumour specimens from 
patients at diagnosis (CHUV hemato-oncology) were analysed. Four μm sections 
were deparaffinated in a xylol bath for 15 min and 5 times rinsed with xylol. Sections 
were rehydrated by transfers in alcohol baths for 5 min with descending 
concentration (100 %, 95 %, 70 %, and 40%) and finally in H20. Then they were 
washed for 5 min in 3 % H2O2 to inhibit endogenous peroxydase. Slides were 
incubated in citrate buffered 10 mM Tris at pH 6 for 5 min and heated in a microwave 
oven for 15 min at 500 W. Monoclonal CXCR4 antibody (monoclonal antibody 12G5, 
R&D Systems, Minnesotta, MN, USA) was added in a dilution of 1:100 in citrate 
buffered 10 mM Tris at pH 6 and incubated overnight. Incubation with secondary 
antibody was performed using HRP EnVision anti-mouse antibodies (Dako, Glostrup, 
Denmark) for 30 min. Treatment with 100 μl DAB+ (Dako, Glostrup, Denmark) at 1:50 
dilution for 8 min, was then performed and slides were mounted using Eukitt (EMS, 
Hatfield, PA). Washings between each step were done in TBS pH 7.6. 
Immunohistochemistry of mouse tumours was performed on fresh frozen sections. 
Cryosections of 7 μm were transferred to SuperFrost®Plus slides (Menzel-Gläser, 
Braunschweig, Germany), air-dried and fixed for 5 min in cold acetone. Slides were 
blocked in TBS-BSA 1% for 10 min at room temperature prior to using anti-GFP 
polyclonal rabbit antibody (BD Biosciences, San Jose, CA, USA). The slides were 
washed and incubated with secondary biotin-conjugated polyclonal goat anti-rabbit 
antibodies (BD Pharmingen, San Diego, CA). Immunostaining was revealed with 
ABComplex/AP (DAKO, Los Angeles, CA) followed by the DAKO Fuchsin Substrate-
Chromogen System. Slides were counterstained with Mayer’s haematoxylin, and 
mounted in permanent medium (Pertex, HistoLab, Göteborg, Sweden). 
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Cell lines 
 
Two main NB cell lines were used in this study: the IGR-NB8 and the IGR-N91 cell 
line. The IGR-NB8 cell line is derived from a xenotransplanted human stage 3 
abdominal NB. IGR-NB8 xenograft and cell line are para-diploid with 1p36 LOH and 
MYCN amplification (112). The IGR-N91cell line was derived from the highly involved 
bone marrow of an 8-year-old boy with stage 4 NB after chemotherapy. IGR-N91 cell 
line is para-diploid, exhibits 1p36 LOH and high MYCN amplification (113).  
Other well established cell lines used in this study as controls include the NB cell line 
SH-SY5Y and the prostate cancer cell line PC3 (114, 115). 
All cell lines were cultured in Dubelcco’s modified Eagle’s medium (D-MEM) (Gibco, 
Paisley, UK) supplemented penicillin/streptomycin (Gibco, Paisley, UK) and 10 % 
heat inactivated FCS (Amimed, Allschwil, Switzerland) and under standard culture 
conditions in a humidified incubator at 37° C with 21% O2 and 5% CO2. 
 
 
Plasmid constructs and transductions  
 
The complete coding region of CXCR4 (1.1 kb) was amplified by polymerase chain 
reaction (PCR) from a cDNA library prepared from the Daudi cell line using 5' and 3' 
primers, each containing a kpnI site (underlined) as follows: sense: 5'-ACG GGT ACC 
ATG TGC CGC ACC CTG GCC GC-3' antisense: 5'-TCC CCA TGG TCA GGT GTG 
TGA GGG CTC GTC-3' The amplified cDNA was subcloned into the pEGFP-C1 
cloning vector to generate a CXCR4-GFP fusion protein. CXCR4 fusion protein cDNA 
was inserted into the retroviral vector pSF1N (116). The pSF1N retrovirus contains 
the murine stem cell virus promoter (117). The plasmid was sequenced for its 
integrity (kind gift from F. Louache, Institut Gustave Roussy, Villejuif, France). 
 
 
Cell surface expression of CXCR4 by FACS  
 
Transduced cells were analysed by FACS and GFP-expressing cells were sorted. 
Clones were randomly selected and further analysed by FACScan (BD Biosciences, 
San Jose, CA, USA) using the direct phycoerythrin labelled 12G5 monoclonal 
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antibody (BD Pharmingen, San Jose, CA, USA) to measure CXCR4 surface 
expression levels.  
Cells were collected, washed in FACS buffer (D-MEM, 10 % FCS, 2 mmol/l EDTA) 
and stained with phycoerythrin-conjugated anti-human CXCR4 mouse monoclonal 
antibody (BD Pharmingen, San Jose, CA, USA) for 15 min at 4 °C. Cells were 
washed twice in FACS buffer and a total of 10’000 events were analyzed by 
FACScan. 
 
 
Semi-quantitative real-time PCR  
 
Relative expression of CXCR4 mRNA was measured with semi-quantitative real-time 
PCR. Total RNA from cell lines was extracted from 2 x 106 cells using the RNeasy 
Mini kit, according to the manufacturers instructions (Qiagen, Hombrechtikon, 
Switzerland). Reverse transcription of 5 μg of total RNA was performed using random 
primers and SuperScript II reverse transcriptase. Briefly, 5 μg of total RNA was 
added to 225 ng random primers and 0.5 mM dNTPs. The mixture was 
complemented with the first strand cDNA buffer, DTT (118) and 200 U of superscript 
II reverse transcriptase (all obtained from Invitrogen, Carlsbad, CA). The relative 
expression of CXCR4 was assessed by real-time semi-quantitative RT-PCR using 
the Light Cycler® system (Roche Diagnostics, Rotkreuz, Switzerland) with SYBR 
Green® detection (Qiagen, Hombrechtikon, Switzerland). Different dilutions of the 
cDNA of interest were quantified using a standard curve performed with the PCR 
fragment of CXCR4 and GAPDH, respectively. The expression level of the CXCR4 
transcript in each cell line was reported to the level of the housekeeping gene 
GAPDH. The primers 5'-AGA TCA TCA GCA ATG CCT CC -3' and 5'- GTG GCA 
GTG ATG GCA TGG AC-3' amplified a DNA sequence of the GAPDH gene of 117 
bp. The 5'-TAT CTG TGA CCG CTT CTA CC-3' and 5'-GCA GGA CAG GAT GAC 
AAT AC-3' primers amplified a 103 bp region of the CXCR4 gene.  
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Chemotaxis assays 
 
Migration assays were developed to quantify migratory capacities of NB cells towards 
the CXCL12 ligand. Migration was measured using Transwell® cell culture chambers 
with polycarbonate filters of 8 μm porosity (BD Biosciences). 2.5 x 105 cells 
suspended in serum-free medium (SFM) were seeded in the upper compartment of 
the two chambers system. The lower compartment was filled with either SFM or with 
SFM containing 100 ng/ml CXCL12 (Peprotech, Rocky Hill, NC, USA). The cells 
were allowed to settle down for 4 hours. After washing with PBS pH 7.2, membranes 
were fixed with 4% paraformaldehyde (Fluka, Buchs, Switzerland) in PBS pH 7.2 
(Laboratoires Dr. Bichsel, Interlaken, Switzerland) for 10 min and stained with 
haematoxylin (Polysciences, Warrington, PA, USA). The non-migrated cells were 
carefully scraped from the upper side of the filter, and migrated cells on the lower 
side counted by light microscopy (Leica Laborlux D). Results are expressed as mean 
number of migrated cells compared to control cells in 10 randomly chosen 
microscope fields.  
Where indicated TN14003 was added to the lower chamber at a concentration of 0.1 
μM and 1 μM directly after the addition of CXCL12. TN14003 was a kind gift of N. 
Fujii, Kyoto University, Japan.  
 
 
In vivo growth  
 
Tumour cells were orthotopically implanted at the Institut Gustave Roussy, Villejuif, 
France in collaboration with Gilles Vassal. Athymic locally bred Swiss nude mice, in 
accordance to the European Community guidelines (directive no. 86/609/CEE) were 
anaesthetized using ketamine 50 mg/kg (Parke-Davis, Berlin, Germany) and xylazine 
35 mg/kg (Provet AG, Burgdorf, Switzerland) i.p.. Orthotopic implantation was 
performed through a midline incision practiced under the microscope. Ten animals 
per cell line were engrafted with 6 x 105 of NB8-E6 cells and NB8-CXCR4-C3 cells in 
15 μl DMEM in the left adrenal gland using a 22 G needle connected to a Hamilton 
syringe. Abdominal wall and skin were closed with a continuous suture of 6.0 Vicryl® 
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(Johnson & Johnson, Spreitenbach, Switzerland). After recovery, the animals were 
kept in a germ-free protected area, with food ad libitum (109). 
Ten animals and 15 animals were grafted with N91-E2 and N91-CXCR4-14 cells, 
respectively (see Figure 3). Two animals in each group died within 24 h after the 
procedure due to perioperative complications (too profound anaesthesia and 
excessive bleeding). Tumour growth was followed by echography to evaluate tumour 
take and size. NB8-CXCR4-C3 and NB8-E6 mice were anaesthetized with ketamine 
in order to measure tumour volume by ultrasound on day 1, 33, and 53. NB8-
CXCR4-C3 mice had to be sacrificed 53 days after implantation. Control mice 
bearing NB8-E6 tumours were measured on the same days as NB8-CXCR4-C3 
tumour bearing animals and again after 69 days and at sacrifice after 102 days.  
Alternatively, N91-E2 and N91-CXCR4-14 cells were implanted as described above. 
Tumour volume was measured weekly and all mice sacrificed after 49 days.  
To evaluate the effect of CXCR4 silencing on in vivo growth, 10 animals per group 
were injected orthotopically with N91-pAB303, N91-shRNA-CS1, and N91-shRNA-
CS2 (2 x 106 cells in 50 μl). One of the N91-pAB303, four of the N91-shCXCR4-CS1 
and two of the N91-shCXCR4-CS1 bearing animals died due to perioperative 
complications. Tumour volume was measured by ultrasound every other week and 
mice were sacrificed after 44 days.  
At sacrifice, mice were examined morphologically for the presence of macroscopic 
metastases.  
To evaluate the presence of micrometastases in different organs, blood was drawn 
by cardiac puncture. The primary tumour, lungs, liver, muscles, and bone marrow 
were carefully removed after rinsing the animal intravenously with 0.9 % NaCl 
containing heparin (5 U/ml). All collected organs were freshly frozen in liquid 
nitrogen. Micrometastases were detected by PCR and macroscopic metastases by 
morphological examination and/or GFP-IHC (109). 
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Figure 3: Schematic view of an orthotopic implantation (left) of NB cells into the left adrenal gland 
of a Swiss nude mouse, right side: Microscopic presentation of a mouse kidney and its adrenal gland. 
 
 
GFP-PCR analyses of organs 
 
Bone marrow infiltration with tumour cells was evaluated by PCR detection of GFP-
DNA sequences specific for injected tumour cells. DNA was extracted from mice 
bone marrow using DNeasy Tissue kit (Qiagen, Hombrechtikon, Switzerland) 
according to the manufacturer’s instructions. PCR amplification of GFP sequences 
was performed using 5’-AGC TGG ACG GCG ACG TAA AC-3’ as forward primer, 
and 5’-CTC GTC CAT GCC GAG AGT GA-3’ as reverse primer. The amplification 
reaction was performed in 50 μl volume containing 1 μl PCR buffer (with 15 mM 
MgCl2), 1 μM of forward and 1 μM reverse primer, 0.2 mM of each dNTP and 2 U 
hotstart-Taq DNA polymerase (Qiagen). Each PCR cycle included: initial denaturing 
at 95 °C for 15 min according to the manufacturer’s recommendations; 37 cycles at 
94 °C for 30 sec, annealing at 59 °C for 45 sec and extension at 72 °C for 45 sec and 
a final extension step at 72 °C for 7 min. The PCR products were analyzed by 1 % 
agarose gel electrophoresis. 
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Cell viability 
 
Twenty thousand cells in 100 μl DMEM containing 2 % or 10 % FCS were seeded in 
quadruplicates in a 96 well plate (Corning Inc, Corning, NY, USA). Cell viability after 
0, 24, 48, 72, and 96 hours was assessed using the MTS/PMS cell proliferation kit 
from Promega (119) (Rocky Hill, NJ, USA). At indicated time points, 20 μl of MTS 
was added to cells and incubated for 2h. Where specified, growth assays were 
performed in the presence of CXCL12 (100 ng/ml). OD was measured using an 
ELISA reader (Dynatech MRX Microplate Reader, Dynatech Laboratories, Chantilly, 
VA, USA). Values are expressed as measured OD x 1000 and were set to an OD 0 
as a baseline (time point 0 h). 
 
 
Ca2+ measurement 
 
One million cells were starved overnight and plated on glass slides with a diameter of 
30 mm (Carl Zeiss AG, Feldbach, Switzerland). Cells were washed once with PBS 
pH 7.2 and loaded with Fluo4-AM (3 μM) (Molecular Probes, Eugene, OR, USA) for 
30 min at 37 °C in loading buffer (136 mM NaCl, 1.8 mM KCl, 1.2 mM KH2PO4, 1.2 
mM MgSO4, 5 mM NaHCO3, 2 mM CaCl2, 6 mM glucose, 20 mM HEPES, and 5mM 
EGTA) (120). The excitation light beam (488-nm, monochromator, Visichrome, 
Visitron; controlled by Metafluor software, Universal Imaging Ltd, UK) was introduced 
through the objective by a long-pass filter (Olympus U-N31001) (Olympus, 
Volketswil, Switzerland); fluorescence emission was collected (cooled CCD camera, 
CoolSNAP-HQ, Roper Industries Inc, Duluth, GA, USA) with a 1-frame per second 
acquisition rate (121). 
 
 
ERK1/2 phosphorylation 
 
Cells were serum starved overnight and washed once with PBS pH 7.2 to 
experimentation (122). One million cells were either unstimulated (depicted as 0 min 
stimulation) or stimulated with CXCL12 at a concentration of 100 ng/ml (Peprotech) 
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for 1, 5, 10, and 30 min. Supernatants were discarded and cells lysed by the addition 
of 500 μl 4 x concentrated sample buffer (250 mM Tris-HCl pH 6.8, 10 % SDS, 40 % 
glycerol, 16 % β-mercaptoethanol, 1 % bromo-phenol-blue). Diluted samples were 
blotted onto Immobilon-P membranes (Millipore, Volketswil, Switzerland). 
Membranes were sequentially blocked for 1h in TBS pH 7.4 containing 5 % BSA at 
room temperature, incubated overnight at 4°C with the phospho-ERK1/2 antibody 
(Cell Signalling, Danvers, MA, USA) followed by 1 h incubation with HRP-labelled 
secondary antibody (DAKO, Zug, Switzerland) at room temperature. The ECL system 
was used for detection (Amersham-Pharmacia Biotech, Piscataway, NJ, USA). 
Subsequently the first antibody was removed by incubation of the membranes for 20 
min at 50 °C in a stripping solution containing 2 % SDS, 65.5 mM Tris-HCl, pH 6.8, 
and 100 mM ß-mercaptoethanol.  
Membranes were subsequently blocked for 1h in TBS pH 7.4 containing 5 % BSA 
and probed with the antibody against the total ERK1/2 (Cell Signalling, Danvers, MA, 
USA) for 1 h at room temperature followed by an 1 h incubation with the secondary 
antibody and revelation using the ECL system.  
 
 
Invasion assays 
 
To measure cell invasion, the 8 μm polycarbonate membranes of the Transwell® 
inserts were coated with 50 μl of 0.8 mg/ml Matrigel® (BD Biosciences). N2-
supplemented (Invitrogen) serum-free DMEM with or without 100 ng/ml CXCL12 was 
added to the lower chamber. 5 x 104 overnight serum-starved cells were added to the 
upper chamber in SFM. The cells were allowed to invade for 48 hours at 37 ° C in a 
humid atmosphere. After incubation, invading cells were fixed and counted by light 
microscopy as described above. Experiments were performed in triplicates. 
 
 
Zymography  
 
Equal cell numbers (0.8 x 105) of different cell lines were plated in SFM to measure 
secreted metalloproteinases activities (MMP-2 and MMP-9). After 12 hours 
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starvation, medium was collected, and MMP-2 and MMP-9 activities were evaluated 
by gelatin zymography (123). Samples were analysed on two 7.5 % SDS-PAGE gels 
in parallel. Gelatine (Merck, Darmstadt, Germany) was added to one of the gels at a 
concentration of 0.1 %. After separation the gels were washed twice in Triton X-100 
2.5 % (Sigma-Aldrich, Steinheim, Germany). Substrate digestion was carried out by 
incubating the gelatine-containing gel at 37 °C for 24 h in 50 mM Tris-HCl (pH 7.6) 
containing 5 mM CaCl2, 1 μM ZnCl2, 1 % Triton X-100, and 0.02 % NaN3. The gel 
was stained with EZ-Blue (BioRad, München, Germany) for 15-30 min. It was kept in 
H2O until visualizing the MMP activity residing in the clear, non-blue zones.  
The control gel was stained with EZ-Blue to check for equal sample loading.  
 
 
CXCL12 ELISA 
 
An ELISA assay (R&D Systems, Minnesota, MN, USA) was used to quantify the 
production of CXCL12 by NB cell lines, normal mouse tissues, and orthotopically 
grown primary tumours. Cultured NB cells were washed once in PBS pH 7.2 and 
suspended in 300 μl lysis buffer containing 10 % protease inhibitors (Roche 
Diagnostics GmbH, Mannheim, Germany). Snap frozen tumours and mouse tissues 
were cut in small pieces and suspended the above described lysis buffer. Sonication 
was performed for 30 min followed by centrifugation for 20 min at 20 000 g. Total 
protein amount was quantified using the Bradford method (Biorad Laboratories, 
Richmond, CA, USA). CXCL12 levels were measured using an ELISA kit (R&D 
Systems Inc., Minneapolis, MN) in triplicates according to the manufacturer’s 
instructions, and the mean values were calculated. 
 
 
Knock-down of CXCR4 by shRNA 
 
Stable downregulation of CXCR4 was achieved by RNA interference using short 
hairpin RNAs (124). A published sequence from shRNA which specifically and 
efficiently down regulates CXCR4 was used as previously reported (Figure 4) (125, 
126). The shRNA oligonucleotides designed contain a sense strand of 21 nucleotides 
followed by a short spacer sequence corresponding to the loop of the shRNA (TTC 
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AAG AGA), the reverse complement of the sense strand, and five thymidines as an 
RNA polymerase III transcriptional stop signal. Forward and reverse oligos were 
annealed and ligated into the BglII/HindIII sites in the pSUPER.ATRi vector (127). 
The sequences were checked by sequencing a PCR-amplified region containing the 
oligonucleotide. The H1 promoter and the shRNA cassette were sub-cloned into the 
BamHI/SalI sites of the lentiviral vector pAB286 containing the SV40 promoter-
puromycin acetyltransferase cassette (128). The pAB303 lentiviral vector which 
contains the H1 promoter alone, without shRNA sequence, was used as a negative 
control (a kind gift from R. Iggo, Aberdeen, Scotland) (128). Lentiviruses were 
produced by co-transducing the lentiviral vector plasmid containing the shRNA (10 
μg) and the second generation packaging plasmids (3.5 μg pMD2-VSVG, 6.5 μg 
pCMVΔR8.91) into 293T (ATCC CRL-11268) (all vectors but pAB303 kindly provided 
by D. Trono, EPFL, Lausanne, Switzerland). Infection of target cells was done by 
over-night incubation at 37 °C in virus-containing media in presence of 8 μg/ml 
polybrene (hexadimethrindibromide, Fluka, Buchs, Switzerland). Twenty-four hours 
post-transfection, the lentivirus containing supernatant was used to infect the IGR-
N91 cell line. Selection was started 48h after infection with 5 μg/ml puromycin 
(Sigma-Aldrich, Steinheim, Germany). Puromycin resistant infected cells were 
selected 24 h post-infection. 
CXCR4 expression knockdown in shRNA-transduced cells was determined by 
semiquantitative RT-PCR analysis as described above.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Schematic diagram showing the structure of the shRNA lentiviral vector with the H1-
shRNA cassette exported from the pSUPER.ATRi vector (126). 
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Microarray hybridization, data collection, and analysis 
 
Cell lines used for microarray analysis were kept in vitro under standard culture 
conditions before RNA extraction. RNA samples were obtained from adherent cells 
using an adapted Trizol-RNeasy method. Cells were detached and Trizol (Invitrogen) 
was added. The solution was homogenized by passing twice through a 26-gauge 
needle. After 10 min incubation at RT, 160 μl  of Phenol/Chloroform/Isoamyl alcohol 
(25:24:1) (Invitrogen) was added. After shaking and centrifugation (4 °C for 15 min at 
12000 g), the aqueous phase was removed and 500 μl of the 
Phenol/Chloroform/Isoamyl alcohol was added, the solution was well mixed by 
shaking and centrifuged as described above. The procedure was repeated twice and 
500 μl ethanol 70 % was added. The solution was loaded onto an RNeasy mini 
column and RNA extracted according to the manufacturers instructions (Qiagen, 
Hombrechtikon, Switzerland). RNA samples were stored at –80 °C until further 
analysis.  
Processing of RNA samples for probe synthesis and microarray hybridization was 
performed at DNA Array Facility (DAFL, Lausanne, Switzerland). For each cell line 
(IGR-NB8 and IGR-N91), three independent clones were hybridized to Human 
Genome U133 Plus 2.0 Affymetrix Genechip Arrays (Affymetrix, Santa Clara, CA, 
USA).  
All statistical analyses were performed using “R” statistical software version 2.0.1 
(http://www.r-project.org). Array quality was assessed using the “affyPLM” package 
from the Bioconductor project (129). Expression values normalized across arrays 
using quantile normalization as implemented in the “Affy” package (130), default 
parameters were used which in particular imply background subtraction. Differential 
gene expression associated to the factors “cell line” and “CXCR4 transduction” was 
assessed by fitting the data to a linear model (with interaction), using the package 
“limma” (131). Foldchange of gene expression as measured by microarray is 
expressed in Table 1 and 2. The p-values associated to the fold changes were 
corrected for multiple testing using the false discovery rate (FDR) method and the 
FDR cut-off level was set at 0.05 (132).  Only genes that are significantly up- or 
downregulated in both cell lines are presented in Table 1 and 2. 
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Statistical Analyses 
 
Statistical analyses were performed using GraphPadPrism 4.0 (GraphPad Software 
Inc., San Diego, CA, USA). Two-way ANOVA with Bonferroni post-test corrections 
was performed to assess invasion assays cell growth in 10 % and 2 % FCS. 
Student’s t test was performed for cell growth in the presence or absence of CXCL12 
and Fisher’s exact test was performed to compare the number of metastasis-bearing 
animals. Mann-Whitney test was used to compare in vivo tumour growth. p < 0.05 
was considered to represent significance. p < 0.01 was considered to be highly 
significant. 
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Results 
 
Immunohistochemical CXCR4 staining on patient's samples 
 
Patient tissue samples of stage 1, 3, and 4 primary tumours were analysed by 
immunohistochemistry for the presence of CXCR4. Three samples per stage were 
analysed and one representative sample of each tumour stage is shown in Figure 5 
A-F.  
While stage 1 tumour cells did not express CXCR4, its expression was found to be 
moderate to high on stages 3 and 4 samples. (Figure 5 C – F). As shown on Figure 5 
E - F, CXCR4 staining was predominantly found on tumour cells and not on vessels 
(red arrow), indicating that CXCR4 staining on the samples was specific. 
Interestingly, CXCR4 expression was also found on non-metastatic stage 3 tumour 
samples (Figure 5 C - D). This analysis confirms the predominant expression of 
CXCR4 on advanced stage NB tumours and thus warrants a further exploration of its 
implication in the aggressive behaviour of the tumours. 
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Figure 5: Immunohistochemistry of NB patient’s samples.  
A and B: Stage 1 tumour. No detectable staining for CXCR4.  
C and D: Stage 3 tumour. Intermediate staining of CXCR4. Some CXCR4 positive cells are visible on 
the 40 x magnification 
E and F: Stage 4 tumour. Strong and specific staining of CXCR4 on most tumour cells. Interestingly 
no CXCR4 expressing tumour cells around the vessel (arrow).   
A, C, and E: 10 x magnification, B, D, and F: 40 x magnification. 
 
 
Expression of the chemokine receptor CXCR4 in different NB cell lines. 
 
CXCR4 expression has been shown to be expressed on particularly malignant NB 
cells (100). We investigated CXCR4 cell surface expression levels in different types 
of NB cell lines. As shown in Figure 6, IGR-N91 and SH-SY5Y cell lines displayed 
constitutive CXCR4 expression levels, measured between 54 % and 97 % CXCR4 
positive cells with mean fluorescence values of 63 and 227, respectively. In contrast, 
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on IGR-NB8 and the prostate cancer cell line PC3 cell lines cell surface CXCR4 
expression could not be detected.  
To investigate the functional role of the CXCR4/CXCL12 axis in NB cells we 
overexpressed CXCR4 in two NB cell lines and in the prostate cancer cell line PC3 
as a control.  
CXCR4 receptor was ectopically overexpressed together with GFP in the non-
metastatic CXCR4-negative IGR-NB8 cell line. Resulting CXCR4 cell surface 
expression was measured in the three selected CXCR4-transduced clones, NB8-
CXCR4-B2, NB8-CXCR4-C3, and NB8-CXCR4-E9 and in the control NB8-E6 GFP-
transduced cells that lack CXCR4. As shown in Figure 6, cell surface CXCR4 protein 
levels in the three selected CXCR4 clones were increased compared to that of IGR-
NB8 parental and NB8-E6 control cells. Levels of CXCR4 surface expression of the 
CXCR4 transduced cells was also higher than of the constitutively CXCR4 
expressing IGR-N91.  
The second NB cell line, which was transduced, is the low metastatic, constitutively 
CXCR4 expressing IGR-N91 cell line. Resulting CXCR4 surface expression of 3 
randomly selected CXCR4 overexpressing clones was high and comparable to the 
CXCR4 transduced IGR-NB8 clones described above (Figure 6). CXCR4 transduced 
clones N91-CXCR4-11, N91-CXCR4-14, and N91-CXCR4-19 expressed much 
higher levels of CXCR4 than mock transduced N91-E2 cells. As compared to the 
parental cell line IGR-N91, CXCR4 surface expression of N91-E2 was slightly lower 
(Figure 6).  
The CXCR4 negative prostate cancer cell line PC3 cells were transduced to express 
CXCR4 as a positive control of another tumour type. Transduced cells represented a 
similar level of CXCR4 intensity as the NB8-CXCR4 and N91-CXCR4 cells (115).  
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Figure 6: FACS analysis of cell surface CXCR4 expression. IGR-NB8 and IGR-N91, two well 
characterized NB cell lines, and transduced cell lines/clones were analyzed. Percent positive cells are 
indicated as well as the mean fluorescent intensity (brackets) of the CXCR4 staining. 
 
 
Levels of CXCR4 overexpression of the IGR-NB8, IGR-N91, and NB8-CXCR4 clones 
were measured by semi-quantitative RT-PCR as shown in Figure 7. Wild type IGR-
N91 cells expressed higher levels of CXCR4 mRNA than IGR-NB8. As expected, 
much higher level of CXCR4 mRNA was measured in the CXCR4 transduced clones 
(NB8-CXCR4-B2, -C3, -E9) compared to wild-type IGR-NB8 and the mock-
transduced NB8-E6 clone. Levels of CXCR4 mRNA expression were concordant with 
CXCR4 cell surface expression (Figure 7)  
 
 
 Results 
- 49 - 
 
 
Figure 7: Semi-quantitative RT-PCR analysis of CXCR4 expression in IGR-N-91, IGR-NB8, mock-
transduced NB8-E6, and 3 selected CXCR4-overexpressing clones. Error bars indicate S.D.. 
Experiment was performed in triplicates and repeated three times. CXCR4 expression of IGR-NB8 
cells was set as 1 and expression levels are presented as relative expression levels.  
 
 
Activation of pERK through the CXCR4/CXCL12 axis  
 
Extracellular regulated kinases 1 and 2 are activated by phosphorylation in response 
to various extracellular signals, including CXCL12 binding to CXCR4 (37). To test the 
functionality of endogenous and transduced CXCR4 in NB cells, we monitored 
CXCL12-mediated ERK 1/2 phosphorylation. As shown in Figure 8, no increase in 
ERK1/2 phosphorylation was detected in the control NB8-E6 cells, in response to 
CXCL12 up to 30 minutes. In contrast, in NB8-CXCR4-C3, N91-E2, and N91-
CXCR4-14 cells, CXCL12 stimulation increased ERK1/2 phosphorylation after 1 
minute already. Total ERK1/2 (t-ERK) protein levels remained unchanged at all time 
points (lower panels in Figure 8). Thus both endogenous and exogenous CXCR4 are 
able to transduce CXCL12 mediated intracellular signals.   
 
 
 
 
Results  
- 50 - 
 
 
 
Figure 8: Western blot analysis of ERK1/2 phosphorylation in response to CXCL12 in CXCR4-
transduced cells. NB8-E6 cells showed no phosphorylation of ERK1/2 upon addition of the ligand. The 
presence of p-ERK1/2 was observed in the CXCR4 expressing cells upon addition of CXCL12.  
 
 
Intracellular calcium release upon addition of CXCL12 
 
An alternative approach to test functionality of GPCR is to measure intracellular 
calcium release (133). No increase in calcium release (fluorescence) was measured 
in NB8-E6 cells upon addition of the ligand. In contrast, a peak of fluorescence was 
detected shortly after addition of the ligand to NB8-CXCR4-C3 cells demonstrating 
functionality of CXCR4 in NB8-CXCR4-C3 cells (Figure 9).  
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Figure 8: Calcium mobilization assay. NB8-E6 and NB8-CXCR4-C3 cells are shown on the left 
panel. Fluorescence (arbitrary units) was measured within the coloured lines. Lines around the cells 
correspond to the extinction curves on the right panels. Addition of the ligand is indicated with red 
arrows. Y-axis indicates intensity of fluorescence expressed in arbitrary units; x-axis reflects time 
(seconds: s).  
Upper panel: NB8-E6 cells did not show an increase in calcium mobilization upon addition of 
CXCL12. 
Lower panel: In the NB8-CXCR4-C3 cells calcium was mobilized upon addition of the ligand. 
 
 
CXCR4 supports cell migration in response to CXCL12. 
 
Migration capacity (chemotaxis and haptotaxis) is a major hallmark of metastatic 
cells, and cell motility represents an initial requirement for cells to invade target 
tissues (20, 38, 52, 53). We therefore measured whether chemotaxis of NB cells was 
influenced by exogenous CXCR4 expression and dependent on the CXCR4/CXCL12 
axis. The different NB cell lines were assayed in vitro for their ability to migrate 
toward CXCL12. As shown in Figure 10, none of the cell lines migrated in the 
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absence of the ligand. In the presence of 100 ng/ml CXCL12, IGR-N91 cells and all 
CXCR4-overexpressing clones migrated towards the ligand, whereas CXCR4 
negative NB8-E6 cells did not. Interestingly, migration of N91-CXCR4 overexpressing 
cells was not further enhanced compared to N91-E2, indicating that chemotaxis 
could not be further enhanced by the overexpression of CXCR4 in constitutively 
CXCR4 expressing cells. 
The specificity of the CXCR4-mediated effect was shown by analysis of cell 
chemotaxis in the presence of CXCL12 and the CXCR4 inhibitor TN14003 (134). 
Whereas TN14003 did not modify the migration of the control cell line, it significantly 
attenuated chemotaxis of CXCR4-expressing clones in a dose-dependent manner 
(Figure 10). These results indicate that CXCR4 is specifically involved in the motility 
of IGR-NB8 and IGR-N91 cells.  
 
 
Figure 10: Cell migration in vitro. Migration of NB8-E6, , NB8-CXCR4-C3, -B2, -E9, N91-E2, and 
N91-CXCR4-14 cells towards CXCL12 in the presence or absence of the specific CXCR4 blocker 
TN14003. Results of one representative experiment are shown and are expressed as the mean 
numbers of migrated cells. Five fields were counted per membrane. The experiment was performed in 
triplicates and repeated at least three times. Error bars indicate S.D.. 
 
 
CXCR4 stimulates in vivo growth in NB8-CXCR4-C3 cells 
 
CXCR4 has been reported to mediate organ-selective metastatic growth in several 
different cancers (44, 46). Furthermore it has been reported that CXCR4 could be 
implicated in the development of site-specific NB metastases (101). We therefore 
investigated whether orthotopic implantation of NB cells overexpressing CXCR4 had 
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an impact on their metastatic dissemination and organ specific secondary growth in 
vivo. To this purpose, we used the recently reported orthotopic mouse model of NB 
that provides conditions which faithfully reproduce the natural microenvironment of 
NB tumours Figure 3 (109). By implanting IGR-N91 NB cells directly into the adrenal 
gland of the nude mouse, we previously showed that a NB tumour could develop and 
disseminate into the liver and bone marrow. 
Control NB8-E6 and NB8-CXCR4-C3 cells were orthotopically implanted in the left 
adrenal gland of nude mice (8 animals per group). These mice were examined by 
echography at day 33, 53, 69 and 102 for tumour growth (Figure 11). Six out of 8 
animals (76%) in the group engrafted with the parental NB8-E6 cells, and 7/8 mice 
(88%) in the group engrafted with NB8-CXCR4-C3 developed a tumour at the site of 
injection. This indicates that overall tumour intake was similar in mice engrafted with 
CXCR4-negative NB8-E6 or positive NB8-CXCR4-C3 cell line (Figure 11).  
The first echographic record performed at day 33 after implantation already revealed 
the presence of tumours with a volume between 100 and 200 mm3 in two mice in the 
NB8-CXCR4-C3 group, whereas no tumour growth was detected in the control 
group. At day 53, 7/8 mice in the NB8-CXCR4-C3-implanted group of mice had 
developed tumours with a mean volume of 1727 mm3, which required the immediate 
sacrifice of all animals in this group. In the NB8-E6 control group, a similar tumour 
intake was observed, with 6/8 animals developing tumours. At sacrifice (day 102), the 
mean volume of tumours was 48 mm3.  Even though the NB8-E6 tumour bearing 
animals were sacrificed much later, the difference in tumour volume is highly 
significant (p < 0.01, Mann Whitney test).  
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Figure 11: In vivo orthotopic tumour growth and tumour take. The mean tumour volume and S.D. 
of NB8-E6 and NB8-CXCR4-C3 tumours as measured by echodoppler at indicated days after 
implantation is shown. The tumour intake is expressed as number of mice with tumour/total mice and 
percent mice with tumours is indicated. 
 
 
CXCR4 is not sufficient to induce metastatic invasion of IGR-NB8 cells 
 
As one of the major proposed roles for CXCR4 was the promotion of site-specific 
metastasis of NB cells, we next investigated whether CXCR4-expressing NB tumours 
displayed increased organ-specific invasive properties. Major target and control 
organs of tumour-bearing mice were analyzed for the presence of metastases.  
Morphological and GFP-IHC examination did not reveal macroscopic liver 
metastases in any mice of either group (data not shown). A GFP-PCR assay was 
developed to reveal the presence of micrometastases. As illustrated in Figure 12, 
liver micrometastases were found in 2/6 CXCR4-negative NB8-E6 tumour-bearing 
mice. GFP-signals were also detected in the lung of a minority of these animals. No 
signal was found in blood, muscle, and bone marrow of either group.  
In the group of mice with NB8-CXCR4-C3 tumours, GFP-PCR signals were detected 
in the liver of 4 out of 7 tumour-bearing animals. One animal in this group had a 
micrometastasis in the lung, but no GFP-PCR signal could be detected in the blood, 
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muscle or the bone marrow of all animals. Although in vivo studies revealed an 
impressive CXCR4-mediated enhanced tumour growth, no change in the metastatic 
pattern was observed as a result of CXCR4 over-expression in these cells.  
 
Figure 12: Distribution of macro- and micrometastases. No macroscopic metastases were 
detected. Liver, lung, bone marrow, blood, and muscle were tested by GFP-PCR for the presence of 
micrometastases. The numbers on the top of the bars represent the numbers of animals with a GFP-
positive signal in that organ vs. the number of tumour bearing animals. No statistical difference was 
found (Fisher's exact test: p = 0.49). Red bars: NB8-CXCR4-C3, green bars: NB8-E6 
 
 
In vivo growth of CXCR4-overexpressing IGR-N91 cells 
 
The above results suggest that in a low metastatic cell line, CXCR4 can strongly 
influence tumour growth without inducing invasion. We investigated whether CXCR4 
could enhance metastatic properties of cells which have described invasive potential 
in the orthotopic NB mouse model (109). Thus, CXCR4 was overexpressed in the 
invasive NB cell line IGR-N91. Three randomly chosen CXCR4-overexpressing 
clones were obtained and the N91-CXCR4-14 clone was selected for further in vivo 
analyses (Figure 6). The N91-CXCR4-14 and mock-transduced N91-E2 cells were 
orthotopically implanted in the adrenal glands of 2 groups of 8 and 13 nude mice. Out 
of 13 mice implanted with N91-CXCR4-14 cells, 12 developed a tumour with a mean 
volume of 1390 mm3 at 49 days, whereas in the control group, 8/8 developed a 
tumour, reaching a mean volume of 15 mm3 after 49 days (Figure 13). N91-CXCR4-
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14 tumours were significantly bigger than N91-E2 tumours (p < 0.05 Mann Whitney 
test). As observed with the NB8 cells, the tumour take was similar in both groups.  
 
 
 
Figure 13: In vivo orthotopic tumour growth and tumour take. In vivo orthotopic growth of N91-E2 
control mock transduced cells and CXCR4 transduced N91-CXCR4-14 clone. The tumour intake is 
expressed as number of mice with tumour/total mice or percent mice with tumours. 
 
 
No significant increase in the number of metastases 
 
The metastatic pattern of these tumours was next analysed. Results shown in Figure 
14 indicate that 6 of 12 tumour bearing mice in the N91-CXCR4-14 group had at 
least one macroscopic liver metastasis, whereas in the control group only 2/8 mice 
developed macroscopic hepatic metastases. Moreover, a tumour volume between 
250 and 1500 mm3 was measured for liver metastases derived from N91-CXCR4 
tumours, whereas it was inferior to 100 mm3 in the control group. In the N91-CXCR4-
14-tumour-bearing mice, GFP-PCR analyses also revealed a positive signal 
indicating the presence of micrometastases in 83 % of the livers, 58 % of lungs, and 
50 % of the bone marrows, while 87.5 % of the livers, 50 % of the lungs, and 25 % of 
the bone marrows were GFP-PCR positive in the N91-E2 group. No signal was 
 Results 
- 57 - 
detected in the blood or muscles in either group. These differences in the occurrence 
of metastases are not significant (Fisher's exact test p = 0.38). It reflects that in vivo 
invasiveness of the N91-CXCR4 cells is not significantly enhanced compared to the 
control N91-E2 cells. In addition, similar frequency and distribution of 
micrometastases in the lungs, liver, and control organs (blood and muscles) was 
found in both groups.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Occurrence of metastases. Macroscopic examination or GFP-PCR-mediated 
identification of organs involved with metastatic NB cells. Macroscopic metastases were only found in 
the liver. Lung, bone marrows, blood and muscles, were investigated by GFP-PCR. Results are 
represented as percentage of mice with GFP-PCR signals or macroscopic metastases in indicated 
organs. Orange bars: N91-E2 tumours, red bars: N91-CXCR4-14 tumours. The number of animals 
presenting at least one metastasis to all tumour-bearing animals is shown on the top of the bars.  
 
 
The CXCR4 ligand, CXCL12 is produced by the tumour microenvironment 
 
The above data indicate that CXCR4 strongly enhances tumour growth in vivo. To 
collect evidence whether CXCL12 may be a factor relevant to tumour growth in vivo, 
we measured the concentration of CXCL12 in the primary and secondary tumours as 
well as in selected host tissues (Figure 15). Presence of CXCL12 could be measured 
by ELISA in several nude mouse organs, and the highest levels of CXCL12 were 
found in the adrenal gland, the natural primary tumour site for neuroblastoma. High 
CXCL12 levels where also found in the liver, lung and muscle, while CXCL12 was 
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almost undectable in the bone marrow (Figure 15). Surprisingly, no direct relationship 
was observed between expression levels of CXCL12 in the different organs and the 
clinical pattern of NB metastasis. In contrast, the high levels of CXCL12 detected in 
the adrenal glands and liver, may be related to the increased primary NB tumour and 
secondary metastatic growth in these tissues. 
 
 
 
Figure 15: CXCL12 production in mouse tissues and NB tumours. The production of CXCL12 was 
measured by ELISA in normal mouse tissues, as well as in the different clones, and primary tumours. 
Results of triplicates are expressed as pg of CXCL12 per mg of extracted protein. One representative 
of three independent experiments is shown. Error bars indicate S.D. of triplicates. 
 
 
CXCR4 does not mediate in vitro NB cell invasion in response to CXCL12 
 
In order to form metastases in vivo, malignant cells need not only to migrate, but also 
to invade basal membranes and the surrounding tissue. To better understand the 
role of CXCR4/CXCL12 axis in supporting cell invasion, we next investigated the in 
vitro invasive properties of NB cell lines and CXCR4-overexpressing clones to invade 
a Matrigel®-coated membrane in response to CXCL12 (135).  
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As shown in Figure 16, in the presence of CXCL12, SH-SY5Y NB cells efficiently 
invaded the Matrigel® during a 48 h incubation period.  
The invasive capacity was similar in the two NB8-CXCR4 clones tested, and only 
slightly above the control cell line NB8-E6. Overexpression of CXCR4 could not 
induce in vitro invasive capacities in the NB8-CXCR4 clones.  
The three N91-CXCR4 clones tested showed similar invasive capacities as mock 
transduced N91-E2. In vitro invasive capacities of N91-CXCR4 cells were not 
increased upon overexpression of CXCR4.  
In contrast to the observation on in vitro invasive capacities made on the NB8-
CXCR4 and N91-CXCR4 cells, overexpression of CXCR4 in the prostate cancer cell 
line PC3 increased invasive properties in vitro significantly (p < 0.05 Student’s t-test). 
The increased in vitro invasiveness of PC3-CXCR4 and the lack of in vitro 
invasiveness of CXCR4 overexpressing NB cells support the hypothesis that the 
effects of CXCR4 overexpression may be cell type specific.  
 
 
 
Figure 16: Invasion of cells through Matrigel®-coated membranes. Bars represent the mean 
number of invaded cells per field (5 fields were counted, cells invaded under SFM were subtracted). 
One representative experiment is shown. Error bars indicate S.D. of triplicates. 
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Measurement of proteolytic activity by zymography 
 
As NB8-CXCR4 overexpressing clones displayed enhanced in vitro migration but not 
invasion nor in vivo metastatic dissemination, we investigated whether the lack of 
invasive properties was related to a lack of proteolytic activities in the parent cells. 
Invasive and metastatic properties of tumour cells are generally provided, at least in 
part, by metalloproteinases (MMP), in particular MMP-2 and MMP-9 (18, 136). In 
addition, several reports described a link between CXCR4/CXCL12 axis and MMP 
activation in invasive cancer cells (137, 138). We measured MMP-2 and MMP-9 
activities in the cell culture supernatant (or cell lysate, data not shown) of SH-SY5Y 
cells, IGR-N-91-E2, NB8-E6 and NB8-CXCR4 clones using a zymography assay 
(Figure 17).  
The NB cells analysed showed variable levels of MMP-2 activity, as evidenced by the 
presence of a unique gelatinolytic band at 72 KD corresponding to MMP-2. 
Consistently with published reports (139), MMP-9 activity was not detected in NB 
cells (data not shown). The addition of CXCL12 to the medium did not influence the 
level of MMP-2 activity (data not shown). Moreover, MMP-2 activity was slightly 
superior in IGR-NB8 cells as compared to IGR-N91 or to the highly invasive SH-
SY5Y cells, indicating that the low invasive capacity of IGR-NB8 cells could not be 
attributed to a lack of MMP-2 activity. The CXCR4 clones did not show increased 
MMP-2 activities compared to the control NB8-E6 cells, showing that CXCR4 
overexpression had no influence on MMP activities, and that invasive properties were 
not solely conferred by CXCR4 or MMP activities. 
 
 
 
Figure 17: Zymography assay of MMP-2 activity in NB cells culture medium. MMP-2 activity is 
represented as a band of gelatinolysis at 72 kDa.  
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In vitro cell growth  
 
To gain further insights into the mechanisms leading to the CXCR4-mediated in vivo 
observed effects, the cell proliferation and survival of the different transduced cell 
lines was measured in vitro in complete medium (10 % FCS) or in stress conditions 
(2 % FCS). Growth curves, established over a 96 hours period, revealed a similar 
growth rate for IGR-NB8 and NB8-E6 cell lines in the presence of 10 % FCS (data 
not shown). In contrast, all three CXCR4-expressing clones displayed moderately 
enhanced growth capacity in 10 % FCS compared to NB8-E6 (Figure 18). The 
difference was not significant for NB8-CXCR4-B2 and NB8-CXCR4-C3 compared to 
NB8-E6.  
Moreover, under suboptimal culture conditions (2 % FCS), NB8-E6 growth was 
significantly impaired. The three CXCR4 expressing clones were only slightly 
affected by these conditions, suggesting a CXCR4-mediated enhanced survival 
under potential stress conditions (Figure 18). All CXCR4 overexpressing cells grew 
significantly faster than mock-transduced controls (two-way ANOVA with Bonferroni  
post test correction). 
 
 
 
Figure 18: Effect of CXCR4 overexpression on NB8 cell growth. In vitro growth of NB8-E6, NB8-
CXCR4-C3, -B2, and -E9 cells, in 10 % or 2 % FCS. Values are expressed as OD (x 1000). Error bars 
indicate S.D. of triplicates. One representative experiment is shown.  
 
 
In the presence of CXCL12, in vitro cell growth of NB8-CXCR4-C3 was significantly 
enhanced compared to NB8-E6 cells (Figure 19) (Student’s t-test).  
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Figure 19: Cell growth in the presence of CXCL12. Increased in vitro cell growth of NB8-CXCR4-C3 
cells compared to NB8-E6 cells in the presence of CXCL12 (100 ng/ml). The growth difference was 
highly significant (p < 0.01) for the NB8-CXCR4-C3 at time point 96 h compared to NB8-E6 (Student’s 
t-test). Values are expressed as OD (x 1000). Error bars indicate S.D. of triplicates. One 
representative experiment is shown. 
 
 
Knockdown of CXCR4 by shRNA 
 
Above results suggest that endogenous and exogenous CXCR4 expression is 
implicated in mediating in vitro and in vivo NB growth. However, in the endogenously 
CXCR4 expressing N91-E2 cells, overexpressing CXCR4 does not further increase 
in vitro growth and invasion. To confirm the growth promoting role of CXCR4 in NB 
we knocked-down CXCR4 in IGR-N91 cells and measured the resulting in vitro and 
in vivo growth.  
Stable knock-down of CXCR4 was achieved by transduction with lentiviral constructs 
of shRNA. After infection and puromycin selection, clones were screened for efficient 
knock-down of CXCR4 by FACS. CXCR4 mRNA levels of cells transduced with the 
empty vector pAB303 were used as reference. Cell surface CXCR4 expression is 
shown in Figure 20. Strong and efficient knock-down of CXCR4 was achieved in both 
clones. CXCR4 expression decreased from 53.4 % in the control N91-pAB303 cells 
to 2.3 % in the N91-shCXCR4-CS1 and 7.7 % in the N91-shCXCR4-CS2 cells, 
respectively.  
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Figure 20: Knockdown of CXCR4 cell surface expression by shRNA. Percent CXCR4 positive 
cells and mean intensity of CXCR4 cell surface expression was diminished in the N91-shCXCR4-CS1 
and N91-shCXCR4-CS2, respectively. Percent positive cells are indicated as well as the mean 
fluorescent intensity (brackets) of the CXCR4 staining. 
 
 
Knockdown of CXCR4 impairs in vitro growth 
 
CXCR4 overexpression in NB cells increased in vitro cell growth under serum-
deprived conditions and in vivo tumour growth. Cells, where CXCR4 has been 
knocked down by shRNA, were tested for their in vitro growth capacities. Both N91-
shCXCR4-CS clones revealed impaired in vitro growth not only in serum deprived 
cell culture conditions (2 % FCS) but also in normal conditions (10 % FCS). The 
difference was highly significant at time point 96 h (p < 0.01, two-way ANOVA with 
Bonferroni post-test correction).  
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Figure 21: In vitro growth capacities of IGR-N91 cells where CXCR4 has been knocked down by 
shRNA. Cells stably expressing CXCR4-shRNA grew significantly slower than control cells. Values 
are expressed as OD (x 1000). Error bars indicate S.D. of triplicates. One representative experiment is 
shown. 
 
 
Knockdown of CXCR4 abrogates in vivo growth  
 
To investigate in vivo growth capacities of NB cells with silenced CXCR4 N91-
pAB303 as control, N91-shCXCR4-CS1, and N91-shCXCR4-CS2 were orthotopically 
injected in mice and tumour growth monitored. All mice were sacrificed 44 days after 
injection because tumour volume of 2 animals of the N91-pAB303 exceeded 1200 
mm3. As shown in Figure 22, 44 days after engraftment N91-pAB303 tumour 
volumes (mean volume 703 mm3) were significantly larger than CXCR4 knockdown 
N91-shCXCR4-CS1 and N91-shCXCR4-CS2 tumours (mean volume 74.8 mm3 and 
9.7 mm3 respectively) (p < 0.05 Mann Whitney test).  
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Figure 22: In vivo growth capacities of IGR-N91 cells where CXCR4 has been knocked down by 
shRNA. Comparison of tumour volumes after 44 days when mice were sacrificed. * indicate p < 0.05 
(Mann-Whitney test). 
 
 
Microarray analysis 
 
The above-described results indicate that CXCR4 overexpression in NB leads to 
increased growth and survival, without conferring enhanced metastatic properties. 
Moreover, knocking-down CXCR4 had a dramatic effect on in vivo growth, 
independently of the level of CXCR4 expression. It is therefore likely that growth and 
survival, rather than invasion pathways are targeted by CXCR4 in neuroblastoma. To 
confirm this hypothesis by a more global approach, gene expression profiling was 
performed to compare the expression profile of CXCR4-negative versus CXCR4 
positive cells. Gene expression profiling was investigated using the Human Genome 
U133Plus2 Set, consisting of two GeneChip® arrays. It contains approximately 
45'000 probe sets representing more than 39'000 transcripts derived from 
approximately 33'000 known or putative human genes. Three mock-transduced 
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clones and three CXCR4 overexpressing clones of both IGR-NB8 and IGR-N91 cell 
lines kept in normal cell culture conditions were used for gene expression profiling.  
Statistical analysis identified 4964 differentially expressed genes with a fold change 
of at least 1.5 and an FDR of 0.05 in the IGR-NB8 group.  In the IGR-N91 group 
2779 genes were differentially expressed using the same cut off levels. Ten genes 
(including CXCR4) were commonly up-regulated in both cell lines (listed in Table 1) 
and 31 commonly down-regulated in both cell lines (Table 2). The fold-change for 
every gene as measured by microarray analysis is shown in the second column of 
the tables (purple). The p-value for every specific gene is also given in the second 
column (blue). Information about protein names, synonyms, and function was taken 
from the Universal Protein Resource homepage (http://www.ebi.uniprot.org/). 
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Discussion 
 
Recent reports strongly support a role for CXCR4 and its ligand CXCL12 in the 
malignant behaviour of cancer cells. In particular, the CXCR4/CXCL12 axis has been 
involved in the directed migration of cancer cells to sites of metastasis, increased 
survival of cancer cells in sub-optimal conditions and establishment of a tumour 
promoting cytokine/chemokine network (12, 38, 44, 52, 53). The overall role and 
specific involvement of the CXCR4/CXCL12 axis in cell proliferation, invasion, 
metastasis, and site-specific spread of NB cells has only been partially investigated 
and remains controversial (101, 102). While it has been proposed that CXCR4 
expression may be a general mechanism by which NB cells metastasise to the bone 
marrow (93), a recent study performed with NB cell lines and patients samples failed 
to confirm this hypothesis (102). CXCR4 was described to be involved in the site 
specific distribution of NB cells when injected intravenously (101). Thus, it remains 
unclear whether CXCR4 is able to confer truly metastatic properties to NB cells when 
implanted orthotopically.  
On primary NB tumour samples, immunohistochemical CXCR4 expression correlated 
significantly with disease outcome. However, when stratified for disease stage, 
CXCR4 was not found to be an independent prognostic factor (100). Despite the low 
number of patient samples included in the study (26 samples), it seems that CXCR4 
plays an important role in advanced stage disease. Interestingly, Russell et al. found 
high CXCR4 expression on stage 3 samples, which is consistent with our results 
(Figure 3). Apart from lymph node involvement, stage 3 tumours are non-metastatic 
tumours. These findings indicate that CXCR4 may not be solely involved in 
metastatic NB tumour progression but play a more general and complex role in 
advanced stage NB tumours.  
In this work, the influence of the CXCR4/CXCL12 axis on the in vitro and in vivo 
aggressive and metastatic behaviour NB cell lines was investigated. Two cell lines 
showing different malignant characteristics were used for this purpose. A stage 3-
derived, non metastatic NB cell line (IGR-NB8), with no detectable cell surface 
CXCR4 expression was selected to investigate whether CXCR4 is capable to induce 
metastasis in non-metastatic cells. A stage 4-derived metastatic NB cell line (IGR-
N91), with moderate constitutive CXCR4 levels was further used to evaluate whether 
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overexpression of CXCR4 would increase metastasis and influence their distribution. 
CXCR4 was stably overexpressed in both cell lines and their in vitro and in vivo 
behaviour investigated. In addition, as a control of CXCR4 induced cellular 
properties, CXCR4 was overexpressed in a cell line derived from another tumour 
type, the prostate cancer cell line PC3 in which effects of CXCR4 overexpression has 
been described (115).  
All CXCR4 transduced cells displayed strong and stable CXCR4 expression as 
checked by semiquantitative RT-PCR and FACS. Interestingly, levels of CXCR4 
expression were similar in all CXCR4 transduced cell lines: both NB and the PC3 
transduced cell lines showed high and comparable fluorescence intensity in the 
FACS analysis (Figure 6). 
The integrity of CXCR4 plasmid used for transduction was verified by sequencing. In 
addition several in vitro assays ensured that a functional receptor was indeed 
transduced. Phosphorylation of ERK 1/2, a downstream target of the 
CXCR4/CXCL12 axis, was rapidly induced upon addition of the ligand to NB8-
CXCR4-C3, confirming the functional transmission of a receptor-binding-mediated 
signal. In contrast, in the N91-CXCR4-14 cells phosphorylation of ERK 1/2 was not 
increased or did not appear earlier when compared to the mock-transduced N91-E2 
cells, as these cells already constitutively express sufficient amounts of functional 
CXCR4. Calcium mobilization upon addition of the ligand is a general characteristic 
of GPCR’s (133). Addition of CXCL12 on NB8-CXCR4-C3 cells led to a rapid 
increase of calcium, which was not observed on NB8-E6 cells (Figure 8).  
Chemotaxis is one of the prerequisites of metastatic cells (7). In addition, mediation 
of chemotaxis by the CXCR4/CXCL12 axis provided a further confirmation of its 
functionality (102). Migration assays revealed that transduced and constitutively 
CXCR4 expressing cells migrated towards the ligand CXCL12, thus contrasting a 
previous report (102) by Airoldi et al. describing high CXCR4 expression on NB 
bone-marrow metastases. The different cell types used in the two studies may 
explain such discrepancy. Whereas we analysed migratory properties of cell lines, 
Airoldi et al. used NB bone marrow metastases samples from patients. All IGR-NB8-
derived CXCR4 transduced clones showed increased migratory capacities compared 
to mock transduced NB8-E6, indicating that migratory capacities could be conferred 
by CXCR4 expression on previously CXCR4 negative cells. Moreover, the pro-
migratory effect of CXCR4 in our study could be blocked in a dose dependent 
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manner by the addition of the CXCR4 specific blocker TN-14003. Furthermore, 
chemotaxis activity in response to the ligand CXCL12 was already observed with 
endogenously CXCR4 expressing N91-E2 cells and was not further increased with 
the N91-CXCR4 cells (Figure 10). As observed in other functional assays, the 
endogenous CXCR4 expression of IGR-N91 cells appears to be sufficient to confer 
NB cells a migratory capacity.  
 
When further investigating the role of the functional transduced CXCR4 receptor in 
neuroblastoma malignant behaviour, the major observation was the highly significant 
increase of in vivo tumour growth as a result of CXCR4 overexpression. Both CXCR4 
overexpressing cell lines NB8-CXCR4-C3 and N91-CXCR4-14 displayed a 
considerably faster growth in orthotopically engrafted mice compared to their 
respective controls. Despite earlier sacrifice of the NB8-CXCR4-C3 group compared 
to NB8-E6 controls, the NB8-CXCR4-C3 tumour volumes 53 days after engraftment 
were highly significantly larger (1727 mm3) than NB8-E6 tumours at 102 days (48 
mm3), revealing a strong growth promoting effect of the CXCR4/CXCL12 axis in vivo.  
Moreover, overexpression of CXCR4 had a similar in vivo effect on N91-CXCR4-14 
compared to N91-E2 tumour growth. At sacrifice, 49 days after engraftment, N91-
CXCR4-14 tumours (1390 mm3) were significantly enlarged compared to control 
N91-E2 tumours (15 mm3) (p < 0.05). The mean tumour volume was thus almost 100 
fold increased. Interestingly, a similar growth promoting effect was also found 
regarding the size of metastases. Liver metastases in the N91-CXCR4-14 group 
were all considerably larger than metastases observed in the N91-E2 group (500 
mm3). This indicates that the growth promotion of the CXCR4/CXCL12 axis is 
simultaneously effective on the primary as well as on the secondary tumour growth. 
The growth-promoting effect of the CXCR4/CXCL12 axis on primary tumours and on 
metastases has also been described by others (54, 140).  
Stable knock-down of CXCR4 has been generated to confirm the in vivo growth 
promotion of the CXCR4/CXCL12 axis (Figure 22). Controls N91-pAB303 and 
CXCR4 knock-down clones N91-shCXCR4-CS1 and N91-shCXCR4-CS2 were 
orthotopically implanted. The main focus of the experiment was to investigate the 
effect of CXCR4 on in vivo tumour growth, hence the experimental setting compared 
to the previous in vivo experiments were adapted to the specific purpose. All mice 
were sacrificed and the experiment was stopped as two of nine N91-pAB303 tumours 
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exceeded 1200 mm3. Mean tumour volume of tumours of the N91-pAB303 group 
(mean volume 703 mm3) was significantly larger than N91-shCXCR4-CS1 and N91-
shCXCR4-CS2 tumours (mean volume 74.8 mm3 and 9.7 mm3, respectively), 
indicating that stable knock-down of CXCR4 by shRNA in the IGR-N91 cell line could 
significantly impair in vivo tumour growth. Endogenous CXCR4 expression knock-
down in the IGR-N91 cell line almost abrogated in vivo tumour growth. Altogether 
these experiments indicate that the CXCR4/CXCL12 axis mediates in vivo NB 
tumour growth.  
In vitro growth assays showed that all CXCR4 expressing NB8 clones displayed 
increased proliferation in 2 % FCS and migratory properties as compared to control 
NB8-E6 cells. One of the three CXCR4 over-expressing (NB8-CXCR4-E9) clone 
revealed a statistically significant increased growth capacity under normal cell culture 
condition. Growth differences of the NB8-CXCR4-C3 and NB8-E6 - the two cell lines 
used for in vivo validation - remained within statistically non-significant limits in 
normal cell culture conditions (i.e. in the presence of 10 % FCS).  
An increase in NB8-CXCR4-C3 cell growth could be observed in the presence of the 
ligand (Figure 19), which was only apparent after 96 h of cell culture. Regarding the 
tremendously increased tumour growth in both in vivo experiments the CXCL12 
growth promoting effect in vitro appeared unexpectedly low. 
 
All CXCR4 overexpressing NB8 clones were significantly less affected by the 
presence of 2 % FCS than mock-transduced controls. As no active ligand is present 
in the FCS (141), it could be excluded that small amounts of CXCL12 were 
responsible for that observation. CXCR4 on the NB8-CXCR4 clones may confer 
capacities, which are independent of the ligand. It appears that receptor signalling 
can also occur even in the absence of the ligand (142, 143). Increasing evidence 
indicates that a single molecular actor can lead to diverse cellular effects depending 
on the environmental conditions. Receptors of the “dependence receptor” family 
create cellular states of dependence on their respective ligands by inducing or 
favouring apoptosis when unoccupied by the ligand, but inhibiting apoptosis in the 
presence of the ligand. Several members are involved in neuronal development and 
migration or axonal guidance. They include receptors which are also implicated in NB 
tumour biology such as p75NTR (144), αvβ3 (145), DCC (146), neogenin (147) and 
RET (148) and ALK (149).  
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CXCR4 most likely does not belong to that group since we do not have evidence that 
apoptosis is induced when the ligand is not present. However, CXCR4 may create a 
cellular state, which is different in the absence of the ligand.  
Overexpression of CXCR4 could not further enhance growth capacities either in 2 % 
FCS or in 10 % FCS of the constitutively CXCR4 expressing cell line IGR-N91 (data 
not shown). However, IGR-N91 cells where CXCR4 has been knocked-down by 
shRNA grew slower in vitro under normal cell culture conditions and under serum 
deprived conditions than control cells.  
Constitutive CXCR4 expression thus seems to be already sufficient to confer CXCR4 
dependent in vitro growth capacities and may not be increased by CXCR4 
overexpression, whereas CXCR4 knock-down of constitutively expressing CXCR4 
cells clearly impairs in vitro cell growth 
The striking difference between the CXCR4-mediated growth promotion in vivo in an 
orthotopic model and its absence of effect on in vitro growth strongly suggest an 
implication of the tumour microenvironment in CXCR4 effects. Unidentified factors 
specifically expressed in the microenvironment of the primary tumour (adrenal gland) 
may synergize with CXCR4 to signal for growth and survival.  
 
The second major and unexpected observation of this study was the lack of observed 
effect of CXCR4 on the in vivo invasive properties of NB cells. Despite the increased 
migratory capacities of the NB8-CXCR4 transduced cells, orthotopic implantation of 
NB8-CXCR4-C3 cells did not reveal induction of macroscopically visible metastases. 
GFP-PCR positive signals for the presence of micrometastases were obtained from 
liver and lungs. Validation of these GFP-PCR results by immunohistochemistry of all 
mice livers revealed no metastases. Some GFP positive may have been missed 
since not the entire organ was screened. Interpretation of GFP-PCR positive signals 
remains difficult and may not always represent the presence of micrometastatic cells, 
which eventually will form a metastasis. However, due to the high specificity GFP-
PCR, negative organs can be considered as truly free of metastases.  
Macroscopic metastases were present in the constitutively CXCR4 expressing N91-
E2 group and the CXCR4 overexpressing N91-CXCR4-14 group. Two of 8 N91-E2 
tumour-bearing animals represented with macroscopic liver and PCR-positive bone-
marrow metastases, compared to 6 of 12 N91-CXCR4-14 tumour-bearing animals. 
This increase in the number of metastases bearing animals upon CXCR4 
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overexpression is very mild and remains not significant in our experimental 
conditions (Fisher’s exact test p = 0.38). The number of metastatic nodules was 
neither increased.  
In contrast to other reports, we could not provide evidence that overexpression of 
CXCR4 in two different NB cell lines induces or increases metastases upon 
orthotopic implantation, and a true demonstration that CXCR4 mediates NB 
metastatic development is still missing. Zhang et al. have reported that CXCR4 
overexpression on NB cells leads to the development of site specific metastases 
when injected intravenously (101). Such tumour models used to study metastasis 
may rather represent advanced stage disease, where tumour cells are already 
disseminated. Several important steps i.e. detachment of the primary tumour, and 
intravasation may be skipped, when tumour cells are injected intravenously (7). 
Whereas orthotopic implantation of tumour cells allows studying all requested steps 
of metastases development (108).  
Though, site-specific metastases were found when CXCR4 was overexpressed on 
melanoma cells, another neural crest derived tumour (150). Although melanoma and 
NB both originate from the neural-crest, they may behave very differently. As an 
example, lack of or low CD44 expression represents a favourable prognostic factor in 
melanoma, while it is associated to MYCN amplification, disease progression and 
poor survival in NB (89, 151). The observation that overexpression of CXCR4 does 
not induce nor increase metastases in NB whereas it does in melanoma maybe also 
a part of their distinctions. Cooperation of CD44 with CXCL12 as recently described 
by Avigdor et al. provides a possible explanation for the different behaviour of these 
two neural crest derived tumours upon overexpression of CXCR4 (152).  
 
High levels of CXCL12 were found in the adrenal gland where tumour cells were 
injected and in the liver where macroscopic metastases were detected. CXCL12 
levels were higher in the adrenal gland than in the liver. This negative gradient could 
be responsible for the lack of increased N91-CXCR-14 metastases in vivo, even 
though these cells presumably were metastatic. It has already been postulated that 
the presence of high levels of CXCL12 in the tumour environment may prevent cells 
from leaving the primary organ by increasing the adherence to collagen IV (153). 
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When measured in vitro, invasive properties of NB cells were also shown not to be 
influenced by CXCR4 overexpression as invasiveness was neither increased in the 
NB8-CXCR4 clones nor in the N91-CXCR4 clones compared to their mock-
transduced controls. Constitutively CXCR4 expressing NB cells SH-SY5Y were 
invasive in vitro and thus appropriate assays conditions to study NB in vitro 
invasiveness have been used. Moreover, overexpression of CXCR4 on PC3 cells 
conferred in vitro invasive capacities, indicating that exogenously enforced CXCR4 is 
capable of inducing invasive properties in other type of tumour cells (Figure 16 and 
(115)). Altogether, invasive properties of cancer cells upon overexpression of CXCR4 
appears to be cell type specific and may not render all types of cancers invasive per 
se. 
In other cancers CXCR4 mediates invasiveness of cancer cells through increasing 
active forms of MMP2 and MMP9 (154, 155). We found release of active MMP2 by 
zymography on in vitro and in vivo invasive cells but also on non-invasive NB8 
derived clones (with or without CXCR4). Thus, the lack of invasiveness cannot be 
explained by diminished release of MMP2 and MMP9 (not shown), respectively.   
 
Microarray analyses of three NB8 and N91 mock transduced and three NB8 and N91 
CXCR4 overexpressing cells revealed genes commonly up- or downregulated in both 
cell lines in the absence of the ligand. Interestingly, more genes (31 genes) were 
downregulated in the NB8-CXCR4 clones and in the N91-CXCR4 clones, whereas 
only 10 genes - including CXCR4 - were upregulated. As it is beyond the scope of 
this work to discuss all deregulated genes, the discussion is focussed on some 
elected ones. Interestingly, genes implicated in the regulation of Rho GTPases were 
differentially expressed in both cell lines. 
The A-kinase anchor protein 13 gene (AKAP13, alias BRX and LBC oncogene) is 
among the upregulated genes. AKAP 13 tethers cAMP-dependent protein kinase to 
its subcellular environment and catalyses Rho GTPases activity as a guanine 
nucleotide exchange factor. The crucial role of members of the Rho family of 
GTPases in carcinogenesis is well established and targeting Rho proteins with 
antineoplastic compounds has become a major effort in the fight against cancer. 
Thus, genetic alterations within the candidate cancer susceptibility gene AKAP13 
would be expected to provoke a constitutive Rho signalling, thereby facilitating the 
development of cancer (156). 
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Three GTPase activating genes of the Rho and one of the Rab family (SRGAP1 and 
SRGAP2, and TBC1D5) are in the list of downregulated genes, indicating an 
important role of downregulation of GTPase activating genes in CXCR4 dependent 
NB growth. SRGAP1 has been reported to play an important role in the axonal 
guidance (157) whereas SRGAP2 upregulation is involved in axonal regeneration 
after axotomy (158). Interestingly, a recent report suggests that TBC1D5 may be a 
tumour suppressor gene (159).  
As genes of the members of the Rho family of GTPases are up- and downregulated 
in both NB cell lines, their dysregulation may lead to the CXCR4 dependent NB 
growth.  
Two zinc finger protein encoding genes were also downregulated in both groups. As 
other Zinc finger proteins are involved in transcriptional regulation and 
downregulation was observed in cancers, they may also be involved in CXCR4 
dependent NB tumour growth (160).  
The differentially expressed genes remain to be validated for their implication in 
CXCR4 dependent NB growth. However, a global impression on genes implicated in 
the CXCR4/CXCL12 axis could be provided by the microarray analyses.  
 
Altogether, the present study demonstrates that the CXCR4/CXCL12 axis plays a 
predominant, tumour type-specific and tumour microenvironment-dependent role in 
NB growth and survival. Although the necessity for CXCR4 signalling in the 
promotion and destination of metastases has not been demonstrated, it is shown that 
CXCR4 expression is not sufficient to confer or enhance the invasive character of 
human neuroblastoma cells.  
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Outlook 
 
CXCR4 expression is found on advanced stage primary human NB tumours and its 
overexpression on NB cells strongly increases in vivo tumour growth in an orthotopic 
NB mouse model. However, we do not have evidence that CXCR4 can confer 
invasive properties to NB cells. This observation requires further investigation and 
may also require a reconsideration of the role of CXCR4 in the metastatic behaviour 
of NB.   
As mentioned above, there is evidence that CXCR4 is mainly found on advanced 
stage tumours. However, these results need further validation on a larger number of 
samples, as it would be available on a tissue microarray. This validation will clarify 
whether CXCR4 expression on primary human NB tumour samples is a prognostic 
factor for disease stage. 
Further evidence is needed about the regulation of CXCR4 on NB cells. Whether its 
expression on NB tumour samples is cause or consequence of advanced stage 
disease. Regarding the enormous growth promoting effect of CXCR4 upon orthotopic 
implantation, the regulatory role of the microenvironment (i.e. the adrenal gland) may 
provide further insights. 
Genes regulated by CXCR4 overexpression identified by microarray analyses need 
further validation. Their behaviour in the presence or absence of the ligand may give 
some insights about their role in the CXCR4/CXCL12 axis. Elucidating the role of the 
CXCR4/CXCL12 axis and implicated genes may reveal new targets for novel 
therapeutic approaches.  
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